

Journal Pre-proof



Perioperative Nutrition: Recommendations from the ESPEN Expert Group

Dileep N. Lobo, Luca Gianotti, Alfred Adiamah, Rocco Barazzoni, Nicolaas E.P. Deutz, Ketan Dhatariya, Paul L. Greenhaff, Michael Hiesmayr, Dorthe Hjort Jakobsen, Stanislaw Klek, Zeljko Krznaric, Olle Ljungqvist, Donald C. McMillan, Katie E. Rollins, Marina Panisic Sekeljic, Richard J.E. Skipworth, Zeno Stanga, Audrey Stockley, Ralph Stockley, Arved Weimann

PII: S0261-5614(20)30179-5

DOI: <https://doi.org/10.1016/j.clnu.2020.03.038>

Reference: YCLNU 4236

To appear in: *Clinical Nutrition*

Received Date: 24 March 2020

Accepted Date: 24 March 2020

Please cite this article as: Lobo DN, Gianotti L, Adiamah A, Barazzoni R, Deutz NEP, Dhatariya K, Greenhaff PL, Hiesmayr M, Jakobsen DH, Klek S, Krznaric Z, Ljungqvist O, McMillan DC, Rollins KE, Sekeljic MP, Skipworth RJE, Stanga Z, Stockley A, Stockley R, Weimann A, Perioperative Nutrition: Recommendations from the ESPEN Expert Group, *Clinical Nutrition*, <https://doi.org/10.1016/j.clnu.2020.03.038>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

1 Perioperative Nutrition: Recommendations from the ESPEN Expert Group

2

3 Dileep N Lobo^{1,2}, Luca Gianotti³, Alfred Adiamah¹, Rocco Barazzoni⁴, Nicolaas E P Deutz⁵,
4 Ketan Dhatariya⁶, Paul L Greenhaff², Michael Hiesmayr⁷, Dorthe Hjort Jakobsen⁸, Stanislaw
5 Klek⁹, Zeljko Krznaric¹⁰, Olle Ljungqvist^{11,12}, Donald C McMillan¹³, Katie E Rollins¹, Marina
6 Panisic Sekeljic¹⁴, Richard J E Skipworth¹⁵, Zeno Stanga¹⁶, Audrey Stockley¹⁷, Ralph Stockley¹⁷,
7 Arved Weimann¹⁸

8

9 ¹Gastrointestinal Surgery, Nottingham Digestive Diseases Centre, National Institute for
10 Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University
11 Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham
12 NG7 2UH, UK

13 ²MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, National Institute for
14 Health Research (NIHR) Nottingham Biomedical Research Centre, School of Life Sciences,
15 University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK

16 ³School of Medicine and Surgery, University of Milano-Bicocca, Department of Surgery, San
17 Gerardo Hospital, Monza, Italy

18 ⁴Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy

19 ⁵Center for Translational Research in Aging & Longevity, Department of Health &
20 Kinesiology, Texas A&M University, College Station, Texas 77843-4253, USA

21 ⁶Department of Diabetes, Endocrinology and General Medicine, Elsie Bertram Diabetes
22 Centre, Norfolk and Norwich University Hospitals NHS Foundation Trust and University of
23 East Anglia, Colney Lane, Norwich NR4 7UY, UK

24 ⁷Division of Cardio-Thoracic-Vascular Surgical Anaesthesia and Intensive Care Medicine,
25 Medical University of Vienna, Vienna, Austria

26 ⁸Section of Surgical Pathophysiology 4074, Rigshospitalet, Copenhagen, Denmark

27 ⁹General and Oncology Surgery Unit, Stanley Dudrick's Memorial Hospital, Skawina, Poland

28 ¹⁰University Hospital Centre Zagreb and Zagreb School of Medicine, University of Zagreb,
29 Zagreb, Croatia

30 ¹¹Faculty of Medicine and Health, School of Health and Medical Sciences, Department of
31 Surgery, Örebro University, Örebro, Sweden

32 ¹²Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

33 ¹³Academic Unit of Surgery, School of Medicine, University of Glasgow, Royal Infirmary,
34 Glasgow, UK

35 ¹⁴Military Medical Academy, Clinic for General Surgery, Department for Perioperative
36 Nutrition, Crnostravska Street 17, Belgrade, Serbia

37 ¹⁵Clinical Surgery, University of Edinburgh, Royal Infirmary of Edinburgh, 51 Little France
38 Crescent, Edinburgh, EH16 4SA, UK

39 ¹⁶Division of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Bern University
40 Hospital and University of Bern, Bern, Switzerland

41 ¹⁷Patient Public Involvement Group, Nottingham University Hospitals, Queen's Medical
42 Centre, Nottingham NG7 2UH, UK

43 ¹⁸Klinik für Allgemein-, Viszeral- und Onkologische Chirurgie, Klinikum St. Georg gGmbH
44 Delitzscher Straße 141, 04129 Leipzig, Germany

45

46

47 **Address for correspondence:**

48 Professor Dileep N Lobo

49 Gastrointestinal Surgery

50 Nottingham Digestive Diseases Centre

51 Nottingham University Hospitals NHS Trust and University of Nottingham

52 E Floor, West Block

53 Queen's Medical Centre

54 Nottingham NG7 2UH, UK

55 Tel: +44-115-8231149

56 Fax: +44-115-8231160

57 E-mail: Dileep.Lobo@nottingham.ac.uk

58

59 Keywords: perioperative nutrition; malnutrition; nutritional assessment; nutritional
60 intervention; perioperative care; sarcopenia

61

62 Word count (excluding title page, abstract, references, figure legends, tables and
63 acknowledgements): 10269

64

65 No. of Figures: 3

66

67 No. of Tables: 4

68

69 **Abstract**

70

71 *Background and aims:* Malnutrition has been recognized as a major risk factor for adverse
72 postoperative outcomes. The ESPEN Symposium on perioperative nutrition was held in
73 Nottingham, UK, on 14-15 October 2018 and the aims of this document were to highlight the
74 scientific basis for the nutritional and metabolic management of surgical patients.

75 *Methods:* This paper represents the opinion of experts in this multidisciplinary field and
76 those of a patient and caregiver, based on current evidence. It highlights the current state of
77 the art.

78 *Results:* Surgical patients may present with varying degrees of malnutrition, sarcopenia,
79 cachexia, obesity and myosteatosis. Preoperative optimization can help improve outcomes.
80 Perioperative fluid therapy should aim at keeping the patient in as near zero fluid and
81 electrolyte balance as possible. Similarly, glycemic control is especially important in those
82 patients with poorly controlled diabetes, with a stepwise increase in the risk of infectious
83 complications and mortality per increasing HbA1c. Immobilization can induce a decline in
84 basal energy expenditure, reduced insulin sensitivity, anabolic resistance to protein nutrition
85 and muscle strength, all of which impair clinical outcomes. There is a role for
86 pharmaconutrition, pre-, pro- and syn- biotics, with the evidence being stronger in those
87 undergoing surgery for gastrointestinal cancer.

88 *Conclusions:* Nutritional assessment of the surgical patient together with the appropriate
89 interventions to restore the energy deficit, avoid weight loss, preserve the gut microbiome
90 and improve functional performance are all necessary components of the nutritional,
91 metabolic and functional conditioning of the surgical patient.

92

93 **1. Introduction**

94 Major surgery evokes a catabolic response that results in inflammation, protein catabolism
95 and nitrogen losses. This response is proportional to the magnitude of the procedure and
96 can, in some instances, be detrimental to the patient, especially when there is pre-existing
97 malnutrition. Traditional perioperative care has involved measures that starve the patient
98 for prolonged periods of time, stress the patient with measures that amplify this response
99 and drown the patient with salt and water overload. However, over the past two decades,
100 there has been a paradigm shift in perioperative care, with periods of starvation being
101 reduced drastically, introduction of measures to reduce surgical stress and protein
102 catabolism, and avoiding salt and water overload. The aim of modern perioperative care is to
103 attenuate loss of or aid return to function in an accelerated manner by promoting return of
104 gastrointestinal function, feeding the patient early, providing adequate pain relief, and
105 encouraging early mobilization. These measures result in reduced complications, early
106 discharge from hospital without increasing readmission rates and better functional recovery.

107 The European Society for Clinical Nutrition and Metabolism (ESPEN) has published
108 updated evidence-based guidelines on perioperative nutrition recently that help aid the
109 nutritional care of the surgical patient [1]. In further support of these guidelines, an ESPEN
110 expert group met for a Perioperative Nutrition Symposium in Nottingham, UK on October 14
111 and 15, 2018. The group examined the causes and consequences of preoperative
112 malnutrition, reviewed currently available treatment approaches in the pre- and
113 postoperative periods, and analyzed the rationale on which clinicians could take actions that
114 facilitate optimal nutritional and metabolic care in perioperative practice. The content of this
115 position paper is based on presentations and discussions at the Nottingham meeting along
116 with a subsequent update of the literature.

117

118 **2. Historical note**

119 Our understanding of the concept of clinical nutrition and the science of human nutrition has
120 evolved significantly over the last two decades. The role of nutrition in surgery has
121 encompassed measures to recognize, identify and intervene in those pre-operative patients
122 who are at risk of malnutrition with appreciable impact on post-surgical outcomes in those
123 adequately nutritionally prehabilitated. However, it would be incorrect to consider clinical
124 nutrition as an entirely new concept [2-4]. Ancient Egyptians were the first to be credited
125 with descriptions befitting enteral nutritional as identified in the Ebers papyrus (c 1550 BC)
126 [4] and feeding via the oropharyngeal and nasopharyngeal routes are from then on
127 described throughout the antiquated medical literature. For instance, Capivaceus in the
128 16th century, Aquapendente in the 17th century [2, 4] and the 19th century physician Dukes
129 [5] employed these routes of nutritional delivery to treat all manner of ailments including
130 mania, diphtheria and croup.

131 The recognition of nutritional deficiency as a cause of illness was first presented by
132 James Lind, a fellow of the Royal College of Physicians of Edinburgh who established the
133 superiority of citrus fruits above all other 'remedies' in his treatise on scurvy published in

134 1753 [6]. The identification, characterization and synthesis of essential vitamins and minerals
135 during the earlier part of the 20th century [7], allowing their use in the treatment of
136 nutritional deficiency-related diseases such as scurvy, pellagra, rickets, and nutritional
137 anemias [7].

138 The adverse effect of weight loss on surgical outcome was documented over 80 years
139 ago when Hiram Studley showed that, in patients undergoing surgery for perforated
140 duodenal ulcer, postoperative mortality was 10 times greater in those who had lost more
141 than 20% of their body weight preoperatively when compared with those who had lost less
142 [8]. This observation generated much of the ensuing work to define the role of malnutrition,
143 nutritional deficiencies, and perioperative nutrition in surgery.

144

145 **3. The malnourished surgical patient**

146 The definition of a malnourished patient is the subject of ongoing discussion. In the last
147 decade there have been considerable efforts to rationalize various definitions generally, and
148 in the cancer patient for whom surgery is commonly the primary modality for cure. The
149 starting point for much of this work was the international consensus of 2011 [9]. In this
150 publication, cancer cachexia was defined as “a multifactorial syndrome defined by an
151 ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully
152 reversed by conventional nutritional support and leads to progressive functional
153 impairment.” There was a recognition of the role of the systemic inflammatory response in
154 the symptoms associated with cachexia. Serum CRP was agreed to be an important
155 biomarker, but it was recognized that cachexia can be present in the absence of overt
156 systemic inflammation [10].

157 In the intervening years with greater knowledge of the importance of systemic
158 inflammatory responses in the progressive nutritional and functional decline of patients with
159 cancer, this statement has been increasingly called into question and measurement of the
160 magnitude of the systemic inflammatory is now integral to the definition and treatment of
161 cancer cachexia [11-14]. This more nuanced definition reflects the evolution of criteria in the
162 definition of malnutrition in which cancer cachexia is considered as part of disease related
163 malnutrition with inflammation [15, 16]. For example, approximately 40% of patients with
164 operable colorectal cancer considered at medium or high nutritional risk (malnutrition
165 universal screening tool – MUST [17]) had evidence of systemic inflammation (CRP>10 mg/L)
166 [18].

167

168 **4. Sarcopenia, sarcopenic obesity and myosteatosis**

169 Patients may present to surgery with a range of underlying nutritional syndromes and
170 phenotypes, such as malnutrition, sarcopenia, cachexia, obesity and myosteatosis.
171 Furthermore, these phenotypes are associated with worsened post-operative outcome.
172 However, screening for such syndromes is not necessarily performed routinely in clinical
173 practice, and there is no one screening tool that is capable of distinguishing one syndrome
174 from another [19].

175 4.1 Sarcopenia

176 A recent study showed that the surgical population in the UK tends to be older than the
177 general population, and that the age gap is increasing with time. Between 1999 and 2015,
178 the percentage of people aged 75 years or more undergoing surgery increased from 14.9%
179 to 22.9%, and this figure is expected to increase further [20]. Sarcopenia is described as ‘the
180 loss of skeletal muscle mass and strength as a result of ageing’. There are a number of
181 definitions for sarcopenia, which rely on the measurement of the combination of both
182 muscle function and muscle mass. These include the European Working Group of Sarcopenia
183 in Older Persons (EWGSOP) [21], the International Working Group on Sarcopenia (IWGS)
184 Sarcopenia Task Force [22], the Asian Working Group for Sarcopenia and the Foundation for
185 the National Institutes for Health (**Table 1**) [10, 21-25].

186 More recently, the term “sarcopenia” has taken on a different usage. The use of
187 diagnostic cross-sectional computed tomography (CT) images at the third lumbar vertebral
188 level (L3) for the simultaneous perioperative analysis of body composition has become
189 increasingly popular [26]. In this surgical context, sarcopenia has come to mean reduced
190 muscularity, without assessment of patient functional status. Rather than assessing skeletal
191 muscle mass, this CT technique analyses cross-sectional skeletal muscle area which is then
192 indexed to patient height to give a skeletal muscle volume. This technique also provides data
193 on the mean skeletal muscle radiodensity, quoted in Hounsfield Units (HU), which is a
194 surrogate marker of muscle quality and an indication of the presence of myosteatosis, as
195 well as adiposity in terms of both visceral and subcutaneous fat cross-sectional area and
196 indices. There is a large volume of literature linking preoperative sarcopenia in a range of
197 different pathologies, including pancreatic surgery [27], gastric cancer surgery [28],
198 esophageal cancer [29], liver transplantation [30] and colorectal cancer [31] to worsened
199 clinical outcomes and overall survival. The strength of this relationship is even greater when
200 the presence of sarcopenia is combined with obesity, i.e. low muscle volume in association
201 with elevated body adiposity. A recent meta-analysis has examined this relationship in 2297
202 patients with pancreatic ductal adenocarcinoma, finding both sarcopenia and sarcopenic
203 obesity to be associated with poorer overall survival (HR 1.49, $p < 0.001$ and HR 2.01,
204 $p < 0.001$) [32].

205 However, there are problems of interpretation in the literature, often due to
206 heterogeneity in the methodology of the studies leading to variability in results. There has
207 been a degree of variability in the cut-offs used for the diagnosis of sarcopenia (and
208 myosteatosis). However, there are well validated BMI and gender-specific cut-offs available
209 in the literature for cancer patients [33]. The validated technique uses CT-based analysis at
210 the L3 level, as this was the level that the initial validation calculations were performed in
211 order to extrapolate to the whole body. Recently, several studies have looked at body
212 composition analysis at the fourth thoracic vertebra as an alternative in patients who are
213 undergoing a thoracic rather than abdominal procedure [34].

214
215

216 4.2 Myosteatorosis

217 Myosteatorosis is the infiltration of skeletal muscle by fat, into both intermuscular and
218 intramuscular compartments. There are a multitude of different terms used synonymously
219 with myosteatorosis, including muscle quality, radiodensity, and muscle attenuation. There has
220 been significant research interest in the impact of myosteatorosis on surgical outcomes in a
221 range of different cancer types, including periampullary [35], ovarian [36] and rectal cancer
222 [37]. As with the relationship between sarcopenia and obesity, there also appears to be a
223 combined effect with myosteatorosis and obesity. In a series of 2100 patients undergoing
224 elective colorectal cancer surgery, three body composition subtypes were independent
225 predictors of hospital length of stay; combined sarcopenia and myosteatorosis (incidence rate
226 ratio (IRR) 1.25,), visceral obesity (IRR 1.25,) and myosteatorosis combined with sarcopenia
227 and visceral obesity (IRR 1.58). The risk of readmission was associated with visceral obesity
228 alone (OR 2.66, p=0.018), visceral obesity combined with myosteatorosis (OR 2.72, p=0.005)
229 and visceral obesity combined with both myosteatorosis and sarcopenia (OR 2.98, p=0.038).
230 There is also emerging evidence that low skeletal muscle radiodensity is involved in the
231 etiology of, or shares mechanisms with, other comorbidities such as myocardial infarction,
232 diabetes and renal failure [38].

233

234 4.3 Cachexia

235 The third body composition syndrome of interest is cachexia, which occurs as a consequence
236 of a range of diseases, including cancer, chronic obstructive pulmonary disease, cardiac
237 failure, renal failure and rheumatoid arthritis. Cachexia is multifactorial in etiology [39]. For
238 example, in patients with cancer, not only is the tumor a potential driver for nutritional
239 depletion, but patients also tend to be older (hence, sarcopenic), live a sedentary lifestyle,
240 and often have a poor diet, as well as have other comorbidities which may impact upon
241 body composition. Recent evidence also suggests that some cancer patients may have a
242 genetic predisposition to weight loss and low muscularity [40].

243 There have been a number of definitions of cachexia published previously [25, 41-
244 43]. However, the most accepted definition of cancer cachexia is "a multifactorial syndrome
245 defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that
246 cannot be fully reversed by conventional nutritional support and leads to progressive
247 functional impairment' [10]. This international consensus provided diagnostic criteria which
248 were either weight loss exceeding 5% or weight loss greater than 2% in individuals already
249 showing depletion as marked by a BMI <20 kg/m² or the presence of sarcopenia.

250 The interaction and overlap between sarcopenia, myosteatorosis and cancer cachexia
251 are not currently well understood. In addition, the interaction between these skeletal
252 muscle variants and patient adiposity and frailty are not clear and these should be the focus
253 of research in the future.

254

255

256 **5. The metabolic response to immobilization and surgical trauma**

257 There are a number of different factors which contribute to the peri- and post-surgical
258 trauma phenotype including immobilization, reduced oral intake, anesthesia, tissue damage,
259 subsequent immune system activation and metabolic changes.

260 There are significant metabolic changes associated with a period of bedrest which
261 are paralleled in the metabolic changes occurring after surgery [44] as immobilization is one
262 of the key components of postoperative changes. These negative changes are also observed
263 in clinical populations and sarcopenic or frail older adults [45] and include a decline in basal
264 energy expenditure, reduced insulin sensitivity, anabolic resistance to protein nutrition,
265 muscle strength and physical performance as well as increased risk of falls, health-related
266 expenditure, morbidity and mortality. The larger impact of bed rest on the rate of loss of
267 lean muscle leg mass and strength during bedrest in healthy older adults than their young
268 counterparts is equivocal [46, 47]. On the other hand, gain of muscle mass and function as a
269 consequence of exercise requires significant regular training over an extended period of
270 time, with evidence suggesting that 12 weeks of resistance exercise training is necessary for
271 a 1.5 kg gain in muscle mass in older adults [45].

272 As the process of muscle loss requires a considerably shorter period of time in older
273 adults, with just seven days of bedrest resulting in 1 kg loss of lean leg muscle mass, there
274 should, therefore, be a particular emphasis on the preservation of muscle mass during
275 periods of muscle disuse whilst older patients are in hospital. This loss of muscle mass occurs
276 in both the type I (slow twitch) and type II (fast twitch) skeletal muscle fibers [48]. In terms
277 of muscle strength, the initial loss of strength occurs rapidly during a period of
278 immobilization, irrespective of the cause of immobilization. However, this loss of strength
279 then plateaus after around 30 days.

280 Older adults tend to stay longer in hospitals and after discharge experience a more
281 pronounced decrease in ambulatory function and reduced ability to complete activities of
282 daily living. There are a number of strategies which have been recommended to reduce
283 muscle wasting during bedrest in older adults, including resistance exercise [49], dietary
284 interventions such as an increase in protein intake to exceed 1 g/kg body weight/day,
285 administration of essential amino acid (EAA) mixtures [50, 51], as well as the combination of
286 these EAA mixtures with carbohydrate [52] or leucine, valine and isoleucine. A study [51] on
287 the role of essential amino acids in older adults undergoing 10 days bed rest found that
288 although this normalized muscle protein synthesis, it did not have an effect upon skeletal
289 muscle loss or function. However, when beta-hydroxy-beta-methylbutyrate (HMB)
290 supplementation was used in a randomized placebo-controlled trial [46] in healthy
291 volunteers undergoing a period of 10 days bedrest, this resulted in a significant reduction in
292 the amount of muscle loss associated with the bedrest as well as an increase in muscle mass
293 gain during the 8 week rehabilitation phase, both in terms of total lean mass and total leg
294 lean mass. Muscle strength also appeared to be preserved in this study.

295 There are many parallels to that associated with immobilization when bedrest as a
296 consequence of surgery is considered. Preoperative fasting is associated with characteristic

297 metabolic changes. After just a short overnight fast, the body remains able to cope with the
298 glucose demands placed on it by the muscle, brain, kidney, bone marrow and lymph nodes
299 by the breakdown of glycogen within the liver. However, after starvation of 24 hours, the
300 metabolic response changes to the breakdown of adipose tissue to mobilize fatty acids
301 which are utilized by the muscle and kidney. When more prolonged periods of fasting are
302 considered, the metabolic response become somewhat more complex. Muscle protein
303 breakdown releases amino acids such as alanine and glutamine which are used in the kidney
304 and liver to promote gluconeogenesis, with persistence of adipose tissue breakdown to
305 provide ongoing energy stores.

306 Resting energy expenditure (REE) increases after surgery, with the degree
307 determined by the magnitude of the insult, with most pronounced changes observed in
308 those following major burns, followed by those with sepsis or peritonitis. Elective surgery is
309 associated with a much lower increase in REE. The metabolic response to surgical trauma
310 allows mobilization of glucose and glutamine to provide substrate for wound healing, and
311 amino acids for acute phase protein synthesis. Intensive care unit stay is also associated with
312 a typical pattern of skeletal muscle loss [53] which is far more rapid than that seen after a
313 standard surgical insult.

314 Surgery results in an overall reduction in lean leg muscle mass [54]. However, when
315 protein turnover is examined, there is not a large difference between the pre- and post-
316 operative phases. When patients are fed postoperatively, this results in a significant increase
317 in protein synthesis rates and reduction in protein breakdown when compared with patients
318 who were fasted postoperatively [54]. Changes in skeletal muscle mass and function
319 following surgery are most likely the consequence of inactivity combined with reduced food
320 intake and specific metabolic changes.

321

322 **6. Nutrition and surgical outcome – lessons from the ESPEN nutritionDay**

323 In the nutritionDay dataset [55] (155 524 patients) 41% of the enrolled participants were
324 surgical patients. The median length of stay for the cross-sectional nutritionDay data
325 collection was 6 days for surgical and non-surgical patients [56]. Surgical patients were 6
326 years younger than non-surgical patients (63 vs. 69 years, $p < 0.001$). BMI was similar in
327 surgical and non-surgical patients. BMI was $< 18.5 \text{ kg/m}^2$ in 7.1% of patients and was > 30
328 kg/m^2 in 19%.

329 Weight loss within the last 3 months was slightly less frequent in surgical patients
330 (39%) than in non-surgical patients (43%) ($p < 0.0001$) while stable weight was more frequent
331 in surgical patients (40% vs. 33%, $p < 0.0001$). Reduced intake in the week before
332 nutritionDay" was slightly less frequent in surgical (44%) than in non-surgical (46%) patients
333 ($p < 0.0001$). On nutritionDay the full served meal was eaten by only 35% of surgical patients
334 vs 38% of non-surgical patients. Nothing was eaten by 20% of surgical patients and 11% of
335 non-surgical patients mostly because they were not allowed to eat. The high proportion of
336 surgical patients with nothing eaten on nutritionDay is shown in **Figure 1** for preoperative,
337 postoperative and non-surgical patients. Artificial nutrition was used in a minority of patients

338 eating nothing. In patients not allowed to eat 30% received artificial nutrition, and in
339 patients eating nothing despite being allowed to eat 27% received artificial nutrition.
340 Reduced eating was associated with a delay in discharge of about 1 day. Outcome at day 30
341 after nutritionDay was available for 83% of patients. Most patients (72.5%) were discharged
342 home 3.8% had died in hospital. Mortality was lower in surgical patients (2%) when
343 compared with non-surgical patients (5%).

344 Weight loss was associated with a slightly higher odds ratio for death in hospital
345 within 30 days in surgical patients when compared with non-surgical patients (OR 3.2 vs 2.5).
346 Reduced intake in the previous week was associated with a progressive increase in death
347 within 30 days from OR 2.0 for less than normal eating, OR 3.6 for eating half and OR 6.4 for
348 eating less than a quarter. This association was similar at all levels to non-surgical patients.
349 Eating half the recommended amount in hospital on nutritionDay was associated with an OR
350 2.3 of death whereas eating nothing despite being allowed to eat was associated with an OR
351 9.0 (Figure 1).

352

353 7. The patient at risk and nutritional assessment

354 The German hospital malnutrition study [57] found that overall 27.4% of patients were
355 diagnosed with malnutrition according to the subjective global assessment (SGA), with a
356 huge degree of variability between specialties. In patients who had undergone major
357 abdominal surgery the prevalence of malnutrition was 44%, with lowest rates in those
358 undergoing chest or general surgery (20% and 14%, respectively). A study of 26 hospital
359 departments spread across the European Union using the nutritional risk screening (NRS-
360 2002) tool identified that 32.6% of patients were at 'high risk' of malnutrition, with these
361 patients developing more complications (30.6% vs 11.3% $p<0.001$), increased mortality rates
362 (12% vs. 1%, $p<0.001$) and longer hospital length of stay (median 9 vs. 6 days, $p<0.001$) when
363 compared with patients who were 'not-at-risk'. A progressive degree of malnutrition, from
364 none to severe, has been associated with progressive increased risk of morbidity and
365 mortality as well as increased ICU admission and overall hospital length of stay in patients
366 undergoing liver transplantation [58]. This relationship of increased morbidity and mortality
367 amongst those with malnutrition is also seen in those undergoing abdominal surgery for
368 cancer [59].

369 Many of the screening tools used historically to identify those at high risk of
370 malnutrition considered only single parameters. However, these do not facilitate the
371 identification of patients' preoperative nutritional status, nor do they precisely identify those
372 at high nutritional risk [60]. A validated screening tool offers a far superior method for
373 identifying those at high risk of malnutrition correctly. Four central criteria were proposed to
374 identify those at high nutritional risk; body mass index (BMI) and a detailed nutritional
375 history, the presence of pathological weight loss, appetite and food intake and the severity
376 of the underlying disease. This led to the development of a range of screening tools including
377 the malnutrition screening tool (MST), the malnutrition universal screening tool (MUST) [17],
378 the nutrition risk index (NRI) [61], the subjective global assessment (SGA) [62], the mini

379 nutritional assessment short form (MNA-SF) [63] and the nutritional risk screening (NRS-
380 2002) [64]. There is only expert consensus regarding the best screening tool available for
381 nutritional risk assessment, which suggests that the MUST is superior in the community, NRS
382 2002 for inpatients and SF-MNA for those in older adult care homes. A multitude of studies
383 have subsequently been performed to validate the predictive value for complications and
384 mortality of preoperative NRS 2002 in patients undergoing surgery, including gastric cancer
385 surgery [65], colorectal surgery [66] and major gastrointestinal surgery [67, 68]. A meta-
386 analysis [69] examining the use of NRS 2002 as a predictor of postoperative outcomes in
387 abdominal surgery included a total of 11 studies. Postoperative complications were more
388 frequent in those deemed 'at risk' than those 'not-at-risk' (OR 3.13, $p < 0.00001$). Mortality
389 was also higher in patients 'at risk' (OR 3.61, $p = 0.009$) and these patients had a significantly
390 longer hospital LOS (mean difference 3.99 days, $p = 0.01$) [69].

391 More recent guidelines [1] have explored criteria for the diagnosis of severe
392 nutritional risk, and these have included weight loss exceeding 10-15% within the preceding
393 6 months, BMI less than 18.5 kg/m^2 , NRS 2002 > 5 or SGA grade C or a preoperative serum
394 albumin concentration less than 30 g/L in the absence of hepatic or renal dysfunction. If one
395 of these criteria is present, targeted nutritional therapy should be instigated immediately. If
396 the screening tools discussed previously identify a patient at risk, a more formal and
397 extensive nutritional assessment should be performed by an appropriately trained
398 professional. This assessment should include nutritional assessment using a plate chart or
399 24-hour dietary recall, estimation of patients subcutaneous and visceral adiposity and
400 skeletal muscle mass, other anthropometrics measures such as upper arm circumference
401 and skin-fold thickness; hand-grip strength as a test of muscle function; and Barthel index or
402 6-minute walking test as a measure of body function [70].

403

404 **8. Preoperative nutritional and metabolic preparation of the surgical patient**

405 Preoperative conditioning is defined as the process of training to become physically fit by a
406 regimen of exercise, diet and rest and is, therefore, regarded as a multimodal intervention.
407 Perioperative oral nutrition is considered one of the major preoperative components of
408 Enhanced Recovery After Surgery (ERAS) pathways [71]. ERAS is believed to help by
409 'exploiting the critical perioperative period to improve long-term cancer outcomes' [72], and
410 optimization of nutrition is one area which can be exploited successfully.

411 The concept of preoperative conditioning is not a new one. In 1992 the concept of a
412 'decision box' [73] which helps to identify the right patients who will benefit most from a
413 nutritional intervention, was devised. Given the high prevalence of malnutrition discussed in
414 the previous section and the known risk factors, which are highly prevalent amongst those
415 undergoing surgery, this should be aggressively targeted. The metabolic risk is exacerbated
416 in patients with malignancy [74] due to release of TNF-alpha, IL-6 and IL-1 in addition to
417 anorexia caused by central nervous system signaling which results in muscle wasting,
418 changes in liver metabolism as well as consumption and depletion of fat stores. Exercise is
419 one modality which can help modulate these metabolic consequences of tumor, by

420 promoting IGF-1, mTOR, and Akt which results in increased protein synthesis; IL-10, sTNF-r1
421 and sTNF-r2 which reduces systemic inflammation; GLUT-4 which reduces insulin resistance
422 and SOD and GSH which results in a reduction in the formation of reactive oxygen species
423 [75].

424 The aims of preoperative conditioning are to restore the energy deficit, improve
425 functional performance, avoid weight loss and preserve the gut microbiome. To obtain such
426 effect, a normocaloric diet is sufficient with a protein intake of 1.2 g/kg [76]. The
427 intervention should include dietary counselling, fortified diets, oral nutritional
428 supplementation (ONS), and parenteral support, where indicated. The enteral route is
429 always preferred wherever feasible and even when patients are consuming a normal diet
430 this is frequently insufficient to obtain their energy requirement, so it is recommended that
431 patients receive oral nutritional supplements (ONS) in the preoperative period, irrespective
432 of their nutritional status [1]. There is good evidence to support ONS in the perioperative
433 period, with a meta-analysis of 9 studies [77] finding this to be associated with a 35%
434 reduction in total complications ($p < 0.001$) and this translated to a cost saving and to be cost
435 effective. In those patients who are identified as high-risk undergoing major abdominal
436 surgery and those who are malnourished with a diagnosis of cancer, ONS should be
437 considered obligatory [1]. In terms of parenteral nutrition (PN), this should only be
438 considered in those with malnutrition or severe nutritional risk where emergency
439 requirements cannot be met by enteral nutrition interventions alone [1]. Where this
440 approach is absolutely necessary, PN should be provided for 7-14 days preoperatively to
441 maximize benefit, based upon evidence that this time frame is necessary to reduce the
442 Clavien-Dindo grade 3b or higher surgical site infection-based complications [78].

443 The use of carbohydrate loading as metabolic conditioning is supported by some
444 basic science and clinical studies [79, 80]. A recent large prospective randomized clinical trial
445 has shown significant benefits regarding the reduction of postoperative insulin resistance
446 and hyperglycemia without impact on the complication rate [81]. So far, the evidence for a
447 decrease of postoperative morbidity is not yet clear.

448 Prehabilitation has gained popularity in recent times, with increasing evidence to
449 support a multimodal prehabilitation program in a range of surgical specialties. A study
450 combining a 6-week preoperative bundle of physical exercise and endurance training,
451 nutrition interventions and psychological support to improve anxiety when compared to
452 postoperative rehabilitation alone [82] in a cohort of patients undergoing elective colorectal
453 surgery found that this optimizes the patients functional capacity throughout the
454 perioperative period. In those patients who are due to undergo preoperative neoadjuvant
455 therapy, the period after cessation of therapy but prior to surgery is typically 4 to 6 weeks
456 and this time should be exploited to optimize patient fitness. A meta-analysis of multimodal
457 prehabilitation [83] in elective colorectal surgery found that this was associated with a
458 significant reduction in hospital LOS of 2 days and was linked to a faster time to return to
459 presurgical functional capacity. When pooled data from RCTs regarding trimodal
460 prehabilitation was analyzed [84], this found that the postoperative loss of lean body mass

461 was attenuated in patients undergoing prehabilitation versus rehabilitation alone. There is
462 also support that a multimodal intervention is associated with improved perioperative
463 physiological parameters, functional outcomes and quality of life measures, but no impact
464 on postoperative complications in those undergoing liver resection [85] as well as a
465 beneficial effect in muscle strength in sarcopenic older adult patients undergoing gastric
466 cancer resection [86]. In high-risk patients undergoing elective major abdominal surgery, a
467 randomized controlled trial found that prehabilitation in the form of a motivational
468 interview, high-intensity endurance training and promotion of physical activity was
469 associated with a significant reduction in the incidence of postoperative complication [87]
470 (31% vs. 62%, $p=0.001$).

471

472 **9. Perioperative glycemic control**

473 Hospital guidelines surrounding perioperative glycemic control are based, in 90% of cases,
474 on the guidance published by Diabetes UK in 2011 [88]. This provides a standard of care,
475 which should be met commencing at the point of referral from primary care, through the
476 perioperative stage and to discharge from hospital. At the first stage when the patient is
477 referred from primary care, the minimum information that should be provided should
478 include the duration and type of diabetes, the place of usual diabetes care (primary or
479 secondary), other comorbidities, and treatment (both for the diabetes and other
480 comorbidities). Information should also be provided on details of any diabetes-associated
481 complications such as renal or cardiac disease, and finally any relevant measures from within
482 the last 3 months, including body mass index (BMI), blood pressure, HbA1c and eGFR.
483 However, the compliance to this standard was low [89].

484 There is evidence supporting an association between the presence of diabetes and
485 significantly elevated risk of 30-day mortality in patients undergoing elective non-cardiac
486 surgery [90]. Those patients with diabetes (20.2%) with preoperative hyperglycemia (7.9%)
487 were twice as likely to die as those with a normal preoperative glucose concentration.
488 However, if the patient did not have preoperatively diagnosed diabetes but had
489 preoperative hyperglycemia, they were 13 times more likely to die within 30 days of surgery
490 when compared with a patient with normal preoperative glucose concentration. When
491 postoperative hyperglycemia was considered, if the patient were not diagnosed with
492 diabetes but had perioperative or postoperative hyperglycemia, they were 45 times more
493 likely to die than those with normal glucose concentration. There is also an association
494 between hyperglycemia in those who were previously normoglycemic and composite
495 adverse events [91], as well as reoperative interventions, anastomotic failures, myocardial
496 infarction and composite infections [92]. However, knowing that the patient was diabetic in
497 the presence of hyperglycemia attenuated these worse clinical outcomes by almost half.
498 There is consistent evidence that the highest risk group with regards to perioperative
499 glucose control are those who are not diagnosed with diabetes but who develop
500 postoperative hyperglycemia.

501 Clinical outcomes in those with poorly controlled diabetes are significantly worse
502 than those with well-controlled diabetes, with a stepwise increase in the risk of infectious
503 complications and mortality relating to infection according to increasing HbA1c (RR 0.98, if
504 HbA1c <6% versus RR 2.01, if HbA1c \geq 11%) [93]. Patients with highest preoperative HbA1c
505 levels tend to have their blood glucose levels checked earlier, have higher postoperative
506 glucose concentrations and are significantly more likely to be commenced on insulin
507 postoperatively, than those with a lower preoperative HbA1c, possibly due to an elevated
508 level of vigilance [94].

509 The current National Institute for Health and Care Excellence (NICE) clinical guideline
510 45 surrounding the use of routine preoperative tests prior to elective surgery suggests that
511 HbA1c should only be routinely tested in those patients with a formal diagnosis of diabetes
512 [95]. However, this is a controversial policy as it fails to identify those patients with non-
513 diabetic hyperglycemia [96] and, therefore, misses the opportunity to intervene
514 preoperatively and modify the elevated perioperative surgical risk that this is associated
515 with.

516

517 **10 Perioperative fluids and outcome**

518 There is a close relationship between nutrition and fluid and electrolyte balance, with the
519 intake of food by natural or artificial means being inseparable from that of fluid and
520 electrolytes [97]. The metabolic response to surgery is associated with salt and water
521 retention and an increase in the excretion of potassium, as a result of which patients are
522 susceptible to retention of salt and water, and consequent fluid overload in the
523 perioperative period [98-103]. There is a relatively narrow margin of safety in perioperative
524 fluid therapy and either too much or too little can have a negative effect on physiological
525 processes and clinical outcome. The goal of perioperative intravenous fluid therapy should
526 be to maintain tissue perfusion and cellular oxygen delivery, while at the same time keeping
527 the patient in as near zero fluid and electrolyte balance as possible (**Figure 2**).

528

529 10.1 Preoperative period

530 Patients should reach the anesthesia room in a state as close to euvolemia as possible with
531 any preoperative fluid and electrolyte imbalance having been corrected. Current anaesthetic
532 recommendations that allow patients to eat for up to 6 h and drink clear fluids up to 2 h
533 prior to the induction of anesthesia help to prevent preoperative fluid depletion without
534 increasing aspiration-related complications. Some patients may need intravenous fluids to
535 restore euvolemia prior to surgery.

536

537 10.2 Intraoperative period

538 Most patients require crystalloids at a rate of 1-4 ml/kg/h to maintain homeostasis [104].
539 However, some patients develop intravascular volume deficits which require correction by
540 administration of goal-directed boluses of intravenous solutions. Goal directed fluid therapy
541 (GDFT) is aimed at maintaining intravascular normovolemia guided by changes in stroke

542 volume as measured by a minimally invasive cardiac output monitor to optimize the position
543 of each patient on his/her individual Frank–Starling curve [105, 106]. In addition to the
544 background crystalloid infusion, fluid boluses (200-250 ml) should be given to treat any
545 objective evidence of hypovolaemia (>10% fall in stroke volume) in order to optimise
546 intravascular volume and cardiac output [107]. A recent meta-analysis that included 23
547 studies with 2099 patients has shown that GDFT was associated with a significant reduction
548 in morbidity, hospital length of stay, intensive care length of stay, and time to passage of
549 feces [108]. However, when patients were managed within ERAS pathways, with optimal
550 perioperative care and avoidance of postoperative fluid overload, the only significant
551 reductions were in length of intensive care stay and time to passage of feces. It has also been
552 shown that GDFT does not impact on outcome when compared with conventional
553 intraoperative fluid therapy in patients undergoing elective colorectal surgery [109]. Hence,
554 within ERAS programmes, it may not be necessary to offer all patients GDFT, which should
555 be reserved for high risk patients or for patients undergoing high risk procedures [104].
556

557 10.3 Postoperative period

558 For most patients undergoing elective surgery, intravenous fluid therapy is usually
559 unnecessary beyond the day of operation, except for those undergoing upper
560 gastrointestinal and pancreatic procedures. With these exceptions, patients should be
561 encouraged to drink as soon as they are awake and free of nausea after the operation. An
562 oral diet can usually be started on the morning after surgery [110, 111]. When adequate oral
563 fluid intake is tolerated, intravenous fluid administration should be discontinued and be
564 restarted only if required to maintain fluid and electrolyte balance. If intravenous fluids are
565 required, then in the absence of ongoing losses, only maintenance fluids should be given at a
566 rate of 25-30 ml/kg/day with no more than 70-100 mmol sodium/day, along with potassium
567 supplements (up to 1 mmol/kg/day) [112]. As long as this volume is not exceeded,
568 hyponatraemia is very unlikely to occur despite the provision of hypotonic solutions [113,
569 114]. Any ongoing losses (e.g. vomiting or high stoma losses) should be replaced on a like-
570 for-like basis, in addition to maintenance requirements. After ensuring the patient is
571 normovolemic, hypotensive patients receiving epidural analgesia should be treated with
572 vasopressors rather than indiscriminate fluid boluses [115, 116]. Fluid deficit or overload of
573 as little as 2.5 L [117] can cause adverse effects in the form of increased postoperative
574 complications, prolonged hospital stay and higher costs due to increased utilisation of
575 resources [118-120].

576 An excess of 0.9% saline causes hyperosmolar states, hyperchloremic acidosis [121-
577 126], and decreased renal blood flow and glomerular filtration rate, which in turn
578 exacerbates sodium retention. Edema impairs pulmonary gas exchange and tissue
579 oxygenation leading to an increase in tissue pressure in organs such as the kidney which are
580 surrounded by a non-expandable capsule. Microvascular perfusion is compromised, arterio-
581 venous shunting increases and lymphatic drainage is reduced, leading to further edema.
582 Hyperchloremic acidosis, as a result of saline infusions has been shown to reduce gastric

583 blood flow and decrease gastric intramucosal pH in older adult surgical patients, and both
584 respiratory and metabolic acidosis have been associated with impaired gastric motility. Fluid
585 overload also causes splanchnic oedema resulting in increased abdominal pressure, ascites
586 and even the abdominal compartment syndrome, which may lead to decreased mesenteric
587 blood flow and ileus, with delayed recovery of gastrointestinal function, an increase in gut
588 permeability, intestinal failure and even anastomotic dehiscence [127].

589 Fluid restriction resulting in fluid deficit can be as detrimental as fluid excess by
590 causing decreased venous return and cardiac output, diminished tissue perfusion and
591 oxygen delivery and increased blood viscosity. It can also lead to an increase in the viscosity
592 of pulmonary mucus and result in mucous plug formation and atelectasis [128]. Induction of
593 anaesthesia in patients with a fluid deficit further reduces the effective circulatory volume
594 by decreasing sympathetic tone. Inadequate fluid resuscitation and decreased tissue
595 perfusion can lead to gastrointestinal mucosal acidosis and poorer outcome.

596 A meta-analysis of patients undergoing major abdominal surgery has shown that
597 patients managed in a state of near-zero fluid and electrolyte balance had a 59% reduction
598 in risk of developing complications when compared with patients managed in a state of fluid
599 imbalance (deficit or excess). There was also a 3.4-day reduction in hospital stay in the near-
600 zero fluid balance group [120].

601

602 **11. Inflammation and surgical outcome**

603 The “trauma of surgery” leads to release of stress hormones and inflammatory mediators.
604 This so-called metabolic stress is akin to the “Systemic Inflammatory Response Syndrome”
605 (SIRS) that follows any injury or infection and is mediated by cytokines. This syndrome
606 induces catabolism of stores of glycogen, fat and protein leading to release of glucose, free
607 fatty acids and amino acids into the circulation – to support the process of tissue healing. It
608 is therefore important to have sufficient protein reserves, preoperatively. This is because
609 current thinking is that, whilst postoperative nutritional therapy may provide the energy for
610 optimal healing and recovery, in the immediate postoperative phase it may only minimally
611 counteract muscle catabolism, or not at all [1]. The consequences of insufficient protein
612 reserves in the postoperative patient includes: decreased wound healing, decreased immune
613 response, defective gut-mucosal barrier and decreased mobility and respiratory effort. All of
614 these would lead to an overall poorer postoperative course [129].

615 11.1 Systemic inflammatory response (SIR)

616 As described in the American critical care medicine consensus [130], SIRS is described by any
617 two of the following: a temperature $>38^{\circ}\text{C}$ (100.4°) or $<36^{\circ}\text{C}$ (96.8°F); heart rate >90
618 beats/min; respiratory rate >20 breaths/min or $\text{PaCO}_2 <32$ mmHg; white blood cells $> 12 \times$
619 10^9 cells/l or $< 4 \times 10^9$ cells/l or $>10\%$ immature (band) forms [130] as well as the absence of
620 a source of an infective focus [130]. In addition to this definition there many
621 pathophysiological changes that occur as part of the systemic inflammatory response (**Table**
622 **2**) [131].

623 11.2 The importance of C-reactive protein (CRP)

624 The prototypical marker of the systemic inflammatory response is CRP. A systematic review
625 that explored routine clinical markers and their association to the magnitude of systemic
626 inflammatory response after surgery – found that even though cortisol, IL-6, WCC, and CRP
627 all peak after all types of elective operations (minor and major, laparoscopic and open), only
628 IL-6 and CRP were consistently associated with the magnitude of the operative injury [132].
629 CRP is routinely measured in clinical laboratories world-wide and used extensively in clinical
630 practice and therefore may be useful in the monitoring and modulation of the SIR after
631 elective operation. A systematic review and meta-analysis that included 22 studies, of which
632 16 studies were eligible for meta-analysis, found that the pooled negative predictive value
633 (NPV) of CRP improved each day after surgery up to 90% at postoperative day (POD) 3 for a
634 pooled CRP cutoff of 159 mg/L [133], and concluded that infectious complications after
635 major abdominal surgery are very unlikely in patients with a CRP below 159 mg/L on POD 3
636 [134]. Another systematic review and pooled-analysis evaluating the predictive value of CRP
637 for major complications after major abdominal surgery calculated a prediction model based
638 on major complications as a function of CRP levels on the third postoperative day [135].
639 Based on the model a two cut-off system was suggested consisting of a safe discharge
640 criterion with CRP levels below 75 mg/L and above 215 mg/L serving as a predictor of
641 complications [135].

642 This work highlights the clinical utility of CRP to identify the magnitude of the effect
643 of surgery on post-operative protein catabolism and clinical outcomes. Also, CRP provides an
644 indicator on which to judge the effect of interventions to mitigate the effects of the SIR in
645 the post-operative period. In this context there is good evidence to support the use of
646 laparoscopic surgery [136] and pre-operative steroids [137]. Also, there is some evidence
647 that supports the use of pre-operative oral antibiotics in combination with mechanical bowel
648 preparation [138, 139].

649 The importance of systemic inflammation and its effects on the surgical patient are
650 summarized in **Table 3**.

651

652 **12. The impact of enhanced recovery after surgery**

653 Enhanced Recovery After Surgery (ERAS) is a relatively new pathway of care for the surgical
654 patient [140]. It is a multi-modal, multi-disciplinary and evidence-based approach to the
655 care, where teams of professionals work together to achieve best practice at all times, but
656 also to be ready and able to adapt and adopt new improvements.

657 The first evidence-based guidance for the entire perioperative care of a patient
658 undergoing major surgery was published in 2005 [71]. The literature showed clear evidence
659 of benefit for avoiding bowel preparation, wound drains, nasogastric tubes, removing
660 urinary catheters, stopping intravenous fluids early and allowing early feeding. Modern
661 fasting guidelines allowing drinking of clear fluids two hours before surgery, and avoiding

662 long acting premedication. Long-acting anesthetic agents and opioids for pain management
663 should be adopted (**Figure 3**). All these treatments had good evidence for their use but were
664 rarely practiced at that time. The evidence is constantly being updated and
665 recommendations may change as the evidence base increases. This is exemplified by that
666 fact that although mechanical bowel preparation on its own is of no benefit [141], the
667 combination of oral antibiotics and mechanical bowel preparation may reduce surgical site
668 infections and anastomotic leaks [139].

669 However, it was found that a protocol on its own was not enough. The care around
670 the patients and the hospital management infrastructure needed to be organized differently
671 [142]. First of all, there is a need to audit what is actually being done with regard to all the
672 recommended ERAS care elements. The patient is passing through several units and
673 different departments during the care process. In each one of these, many professionals are
674 managing their specific focuses for the time they have the patient to care for. Once done,
675 they pass the patient over to the next care giver. The complexity of the organization is such
676 that no one has any overview or full control of the entire care pathway. This was a primary
677 need that was addressed by the ERAS group by instituting audit for each and every patient.
678 Since the patient is treated by many different professionals and they work in different parts
679 of the hospital, it was necessary to form teams that covered all stations and all professions.
680 This was the birth of the ERAS Team. This team is led by doctors from surgery and anesthesia
681 who take the medical responsibility for the care that is delivered and administrated and run
682 by nurses led by an ERAS coordinating nurse.

683 A major breakthrough for ERAS came in 2010 when it was reported in meta-analysis
684 that ERAS reduced complications [143]. Now the data suggested 50% reductions in
685 complications in colorectal surgery. This sparked a lot of interest and soon ERAS principles
686 were employed for most major operations in randomized trials and care series, all showing
687 similar outcomes with faster and better recovery [144]. This also held true for the most
688 vulnerable patient groups such as the frail and older adults [145]. ERAS also reduces the
689 impact of risk factors including diabetes [146], undernutrition [147] and facilitates optimal
690 metabolic and nutritional care [148].

691 When ERAS is combined with minimally invasive surgery poor compliance to the
692 protocol may overshadow the risks associated with co-morbidities [149]. The main
693 mechanisms behind these improvements are likely to be associated with the marked
694 reduction in stress reactions to the surgery, since many of the elements of ERAS have this
695 effect [150]. In colorectal surgery, better compliance with the protocol results in shorter
696 stay, fewer readmissions, fewer complications [151, 152] and is associated with improved 5-
697 year survival [153].

698 The variation in care delivery and outcomes is huge worldwide [154], within
699 continents (76), in countries [155] and between different practitioners [156, 157]. Much of
700 this variation is due to the slow adoption of modern care and the practice of old and
701 outdated care principles. The reasons for this are many, but it is interesting to find that the
702 implementation program run by the ERAS Society has proven to work in all major continents

703 and in different socio-economic environments. With the marked reduction in complications
704 and the opening up of resources with faster recovery and shorter stay the economics of
705 ERAS is positive regardless of financing of the health care system [158].

706 In summary, the evidence-based multi-modal and multi-professional approach to
707 perioperative care – ERAS – has been shown to markedly improve surgical outcomes and
708 save cost for care.

709

710 **13. Recovery in the community**

711 Following a successful perioperative hospital stay, setting of expectations and thorough
712 preparation are key to a successful discharge from hospital including pain management,
713 nutrition, the use of laxatives for return of bowel function, appropriate exercises to help
714 regain normal function, and having a contact point for any questions. Information should
715 also be provided surrounding symptoms to be wary of which may indicate the presence of a
716 complication and what to expect in terms of follow-up. There is good evidence that nursing
717 telephone follow-up following discharge is positive in terms of providing support and
718 reassurance for patients [159], as well as reducing hospital readmission rates and improving
719 patient satisfaction. The process of expectation setting commences with preoperative
720 counselling [160] where the patient is provided information regarding what to expect on a
721 daily basis after surgery, identifying the resources available to the patient to facilitate
722 smooth recovery, and what the patient can do to optimize their outcome. This information
723 giving is frequently backed up with comprehensive guides and booklets to help them better
724 understand ERAS programs. In terms of post-discharge from hospital, support from the
725 district nurse or home helper is invaluable in providing information regarding adequate
726 nutrition, continued rehabilitation and exercise.

727

728 **14. Postoperative nutrition**

729 The instigation of postoperative nutrition should be a part of routine care rather than an
730 afterthought. In addition, ensuring establishment of early oral nutrition is a fundamental
731 tenet of ERAS [1].

732 The mode of nutritional delivery in the early postoperative period has been a subject
733 of much debate, especially in procedures involving the formation of bowel anastomosis.
734 However, several studies and systematic reviews with meta-analysis have concluded that
735 oral and/or enteral is the preferred mode of nutrition for surgical patients. A review of five
736 feeding routes following pancreaticoduodenectomy showed that nutritional delivery via the
737 oral route was associated with the least complications [161]. A more recent meta-analysis
738 using only randomized controlled trials showed enteral to be superior to parenteral nutrition
739 following pancreaticoduodenectomy [162].

740 Avoidance of oral intake, which was felt to reduce the risk of complications,
741 especially after gastrointestinal surgery involving anastomosis has not been demonstrated in
742 the setting of any randomized controlled trials. However, this avoidance of nutritional intake

743 carries the very real risk of postoperative underfeeding of an already at risk patient group.
744 This could further exacerbate malnutrition and influence postoperative complication rates.

745 There is a distinct requirement of the understanding of this metabolic response and
746 how to optimize or support the postoperative patient with the appropriate nutritional
747 therapy especially in instances when the patient is malnourished. The long term caloric and
748 protein deficits in the post-surgical patient results in poorer postoperative outcomes.

749 14.1 Early postoperative nutrition

750 Early nutrition has been shown in abdominal and pelvis surgery to stimulate peristalsis and
751 GI excretion, reduces the risk of postoperative ileus and shortens overall hospitalization
752 period. It was observed that patients who had earlier enteral feeding had fewer
753 complications after colorectal surgery (4.5%) vs 19.4% late enteral nutrition [163]. A
754 Cochrane review on early enteral nutrition also showed no difference in risk of postoperative
755 complications in patients fed early (within 24 hours) and those fed late. Importantly they
756 showed that patients who were fed early had a reduction in mortality RR (0.41, 95% CI 0.18
757 to 0.93) [164]. An updated review on the same premise found reduction in length of hospital
758 stay but was inconclusive on postoperative outcomes and quality of life [165].

759 14.2 Routes of feeding

760 The current ESPEN guidelines state that 'Oral nutritional intake shall be continued after
761 surgery without interruption and oral intake, including clear liquids, shall be initiated within
762 hours after surgery in most patients' [1]. Perioperative nutritional support therapy is
763 indicated in patients with malnutrition and those at nutritional risk. Perioperative nutritional
764 therapy should also be initiated, if it is anticipated that the patient will be unable to eat for
765 more than five days perioperatively. It is also indicated in patients expected to have low oral
766 intake and who cannot maintain above 50% of recommended intake for more than seven
767 days. In these situations, it is recommended to initiate nutritional support therapy without
768 delay.

769 This is further supported by the systematic reviews and meta-analysis on several
770 gastrointestinal surgical procedures that have shown no increased benefit of food avoidance
771 and indeed better outcomes in the patients that received oral nutrition and those that were
772 enterally fed [161, 164-166]. In all of these instances they found that early enteral and oral
773 nutrition was not associated with an increase in clinically relevant complications, but rather
774 a shorter length of hospital stay [161, 162, 165, 166]. Only in cases If the energy and nutrient
775 requirements cannot be met by oral and enteral intake alone (<50% of caloric requirement)
776 for more than seven days, a combination of enteral and parenteral nutrition is
777 recommended [1].

778

779

780

781 15 Postoperative exercise intervention

782 Exercise stimulates muscle capillarization, protein synthesis, insulin sensitivity and
783 mitochondrial function and proliferation, and therefore is a good strategy to maximize
784 postoperative recovery. However, robust voluntary exercise intervention postoperatively at
785 a time when metabolic dysregulation and fatigue are at their greatest is unlikely to be
786 practicable, and fatigue may persist for many weeks after surgery [167]. Furthermore,
787 muscle wasting and deconditioning will be exacerbated by prolonged periods of bed-rest
788 [44]. In this situation, non-voluntary, transcutaneous, electrically evoked muscle contraction
789 may be an effective strategy for the maintaining or improving muscle mass and function
790 after surgery until voluntary exercise, which is likely to be most effective, is practicable
791 [168]. Given muscle mass restoration following wasting is known to be slower and of less
792 magnitude in older people [169], resistance exercise intervention in older people will need
793 to be supervised and intensive to be successful. Patient muscle mass restoration may be
794 augmented if exercise intervention is combined with protein nutrition, although this is
795 controversial providing the volunteer is in protein balance[170].
796

797 16. The role of novel nutrients and substrates

798 In the last decades, standard enteral and parenteral formulas have been supplemented with
799 specific nutrients and substrates with the goal of improving several metabolic pathways,
800 which are deranged by surgical injury. The peculiar and unique mechanisms of action of
801 some substrates, established first in experimental settings, encouraged the induction of
802 clinical trials.
803

804 16.1 Glutamine

805 Glutamine is involved in a variety of biological processes, such as anabolic functions, acid-
806 base regulation in the kidney, and ammonia metabolism [171]. Depletion in glutamine
807 storage during stressful events [172] has been reported, and an exogenous supplementation
808 is associated with improved protein synthesis, preservation of gut barrier, enhancement of
809 wound healing, reduction of oxidative stress, negative nitrogen balance, improvement of
810 glucose metabolism, and modulation of the immune system [173].

811 Until 2007, several randomized, but underpowered, clinical trials (RCTs) have been
812 published and when the results were pooled in a meta-analysis [174], the effect of
813 parenteral or enteral glutamine supplementation resulted in a significant reduction of
814 surgical morbidity and duration of hospitalization. In 2009, the largest RCT (n=428) on the
815 impact of the parenteral glutamine supplementation (0.4 g/kg/day) in major abdominal
816 operations for cancer, rejected the hypothesis of a protective effect on any type of surgery-
817 related morbidity and on the length of hospital stay [175]. More recently a multicenter
818 double-blind RCT was reported including 150 surgical ICU patients without renal or hepatic
819 failure, or shock. All received isonitrogenous isocaloric parenteral nutrition (1.5 g/kg/day). In
820 the intervention group, glutamine was administered in the standard dosage of 0.5 g/kg/day.
821 No significant differences were seen with the primary endpoints of hospital mortality and

822 infection rate (mortality glutamine vs. standard 14.7% vs. 17.3%, bloodstream infection rate
823 9.6 vs. 8.4 per 1000 hospital days) [176].

824 A recent meta-analysis [177], included 19 RCTs with 1243 patients scheduled for
825 elective major abdominal surgery. Glutamine supplementation did not affect overall
826 morbidity (RR = 0.84; p = 0.473) and infectious morbidity (RR = 0.64; p = 0.087). Patients
827 treated with glutamine had a significant reduction in length of hospital stay.

828

829 16.2 Omega-3 fatty acids

830 Fatty acids are potent modulators of the immune and inflammatory responses. They are
831 incorporated into the cell membrane influencing the function and structure. By penetrating
832 into the cell cytoplasm, fatty acids affect the synthesis of eicosanoids, cytokines and several
833 other key mediators. Furthermore, they impact on gene expression and cell signaling. In
834 addition, the cell-mediated immune responses are deeply affected by different type of fatty
835 acids. Specifically, omega-3 fatty, as opposite to omega-6 acids, stimulate the synthesis of
836 less proinflammatory leukotrienes, prostaglandins, and thromboxanes [178].

837 Despite the strong molecular background, robust clinical studies on the effect of
838 parenteral formulas containing omega-3 fatty acid-based lipid emulsion are limited. The
839 largest RCT on this topic showed no significant difference between treatment and control
840 arms in postoperative complication rates with an associated and unexplained 5-day
841 reduction in LOS in the group receiving omega-3 fatty acids [179]. A recent systematic review
842 and meta-analysis collected 49 RCTs addressing the impact of omega-3 fatty acids on surgical
843 outcomes [180], but only 24 studies, with a total of 2154 patients, reported the rate of
844 postoperative infections. Regardless of the commercial formulation used, the risk ratio was
845 in favor of the group receiving omega-3 fatty acids (RR=0.60; 95%CI [0.490, 0.72]). As
846 properly emphasized by the authors, the major constraint of this meta-analysis [180], as well
847 as others [181], was the inclusion of underpowered and non-significant trials. This limitation
848 could have produced overstating results.

849

850 16.3 Enteral feeds containing multiple substrates

851 Most of the evidence suggesting that specific nutrients may modulate the clinical course of
852 patients undergoing major operations has been produced by testing, enteral or oral formulas
853 enriched with arginine, omega-3 fatty acids and ribonucleotides [182, 183].

854 The evidence has been extensively argued and reported in the 2017 ESPEN guideline
855 on clinical nutrition in surgery [1]. The author recommendations were as follows: “peri- or at
856 least postoperative administration of specific formulae enriched with immunonutrients
857 should be given in malnourished patients undergoing major cancer surgery. There is
858 currently no clear evidence for the use of these formulae enriched with immunonutrients
859 *versus* standard oral nutritional supplements exclusively in the preoperative period”. These
860 statements were based after the authors’ systematic search for studies and reviews
861 published between 2010 and 2015. However, a recent focused meta-analysis on
862 preoperative immune modulating nutrition in gastrointestinal cancer only, has

863 demonstrated a significant reduction in infectious complications and tendency to a shorter
864 length of stay [182].

865 It should be highlighted that the vast majority of the published RCTs on
866 immunonutrition in surgical patients were conducted outside the implementation of ERAS
867 protocols. The beneficial effect of the administration of immunonutrients, in addition to
868 ERAS pathways has been addressed in recent multicenter Spanish RCT [184]. They studied
869 this association in well-nourished patients undergoing colorectal resection for cancer. The
870 findings demonstrated a decrease in the total number of complications observed in the
871 immunonutrition treated group compared with the control group, primarily due to a
872 reduction in infectious complications (23.8% vs.10.7%, $P=0.0007$). These findings look
873 promising but necessitate future confirmations.

874

875 **17. Pre-, pro- and syn-biotics in the surgical patient**

876 Probiotics, as defined by the World Health Organisation are live microorganisms which,
877 when administered in adequate amounts, confer a health benefit on the host. They survive
878 transit through the gastrointestinal tract with the majority of their activity being in the colon
879 [185]. Prebiotics are carbohydrate compounds, primarily oligosaccharides which induce
880 growth and/or activity of selective bacterial genera in the colon [186]. Combinations of
881 prebiotics and probiotics in a single preparation are referred to as synbiotics [185]. Current
882 literature suggests that multispecies preparations are more effective due to better survival
883 of the gastro-duodenal passage or greater ability to find a biological niche. However, to date,
884 the most appropriate species of probiotic has not been described in the currently available
885 literature.

886 Probiotics have been used in the treatment of several abdominal complaints. They
887 have been shown to be useful in the treatment of gastrointestinal infections, for oral
888 rehydration therapy in treating acute infectious diarrhea in children [187-190], traveller's
889 diarrhea [191] and antibiotic-associated diarrhea in both children [192-194] and adults [195-
890 198]. Recent ESPEN guidelines stated that use of a specific probiotic multi strain mixture may
891 be beneficial for primary and secondary prevention of pouchitis in patients with UC who
892 have undergone colectomy and ileo- anal pouch anastomosis. There are some data to
893 confirm the use of the same multi strain probiotic mixture for the treatment of pouchitis
894 after antibiotic treatment failure as well as for the treatment of mild to moderate ulcerative
895 colitis [199]. The suggested mechanisms of action include both a direct antimicrobial effects
896 as well as indirectly or competitively excluding potentially pathogenic bacteria [200]. They
897 achieve this by producing bacteriocins which inhibit pathogenic epithelial adherence and
898 production of virulence factor, and prevent bacterial translocation via tight junctions [200,
899 201]. They also alter gut microenvironment by altering the mucosal pH, which further
900 inhibits pathogenic bacteria. Additionally, others have shown that probiotic bacteria can
901 hamper the inflammatory response by promoting anti-inflammatory cytokine production
902 [200, 202]. Whilst these nutritional adjuncts are emerging as potential treatments that could

903 help reduce the incidence of postoperative infection, the success or failure of one strain
904 cannot be extrapolated to other strains.

905 To the post-surgical patient, the stress of the operative procedure can lead to a
906 proinflammatory stimulus that increases gut permeability. Increased gut permeability
907 together with dysbiosis may lead to increased bacterial translocation across the gut barrier
908 into the circulation. Bacterial translocation is an important pathogenic factor for the
909 increased risk of infections. To this end the introduction of probiotics or synbiotics would be
910 expected to maintain gut barrier function by restoring intestinal permeability ameliorating
911 the intestinal inflammatory response and the release of cytokines, and maintaining the
912 homeostasis of the normal gut microbiota.

913 A number of randomized controlled trials (RCTs) have examined the value of
914 prebiotics and probiotics in reducing postoperative complications in particular post-
915 operative infective complications. The interest in synbiotics, is based on emerging evidence
916 that the proliferation of probiotic bacteria can be enhanced by the co-administration of
917 prebiotics [203]. Indeed a more recent meta-analysis has shown that whilst infectious
918 complications were reduced after elective abdominal surgery, the effect was better still in
919 those patients who received synbiotics [204].

920 Contrastingly, some studies have yielded mixed results that probably are due to the
921 variations of probiotics used, methodological quality and study endpoints. Additionally,
922 others have described adverse events surrounding probiotics use. It is, however, noteworthy
923 that serious adverse effects of probiotics are uncommon in those who are well. In patients
924 with severe pancreatitis, administration of probiotics was associated with an increased
925 frequency of bowel ischemia – the mechanism of this is still unexplained [205-207].
926 However, this effect of probiotics has not been identified in any other study. In the most
927 recent meta-analysis [204], no serious adverse events were noted. They concluded that
928 probiotics and synbiotics are safe in elective gastrointestinal surgery and is associated with a
929 significant reduction in infectious complications.

930

931 **18. Patient and caregiver partnership**

932 The period surrounding a major surgical procedure is highly taxing on patients and their
933 caregivers. Perioperative nutrition is recognized as a substantial issue, with significant
934 weight loss not uncommon. Malnutrition in this setting is multifactorial, including issues with
935 poor appetite, unappealing hospital nutrition, postoperative pain and a reduced level of
936 consciousness. Support from family is frequently key to optimizing perioperative nutritional
937 intake and modification of previous eating habits including consuming high calorie foods on
938 a little but often basis. Oral nutritional supplementation is often met with variable patient
939 acceptability and hence compliance is often not optimal. The effects of major surgery and
940 indeed the complications, have wide reaching effects on not just the patient but also their
941 families and caregivers, rendering them a bystander in the care of their loved ones. The
942 importance of communication cannot be overemphasized in this setting, and a strong

943 partnership between the surgeon and patient, family and caregivers is needed to overcome
944 complicated postoperative courses.

945

946 **19. Future directions for research and policy**

947 The evidence contains many strengths, and these are reflected in high-quality guidelines
948 surrounding perioperative nutrition [1]. However, there are still many areas of nutrition in
949 this setting which have not yet been fully explored. An area of research development
950 surrounds the global obesity epidemic and its link to metabolic syndrome, with more
951 attention being directed towards a multidisciplinary approach to the management of obesity
952 and its related diseases [208], tying together concepts such as bariatric and orthopedic
953 surgery, geriatrics, endocrinology, psychology and psychiatry, as well as nephrology and
954 dialysis. An area of research which is going to become increasingly relevant is the shift in
955 population related to the ageing epidemic which is currently underway. With increasing
956 frailty comes weight loss, progressive skeletal muscle weakness, exhaustion and inactivity,
957 all of which increase the prevalence of disability, loss of independence and worsened clinical
958 outcomes.

959 Not only are there challenges in developing an evidence base for interventions, but
960 also in the implementation of this evidence once established. One area in which
961 implementation lags behind the evidence base for its practice is ERAS protocols in surgery,
962 with a multicenter qualitative study finding the main barriers to implementation being time
963 restraints, a reluctance to change and the logistics of setup [209]. Another topic is that of
964 fasting guidelines in enterally fed in critical care patients. Again, this identified issues
965 surrounding mistrust of the guideline, resistance to a change in clinical practice, as well as
966 perceived increased clinical complexity which all acted as barriers to implementation. There
967 are some key concepts which are necessary for increasing implementation which include
968 promotion of education including resources such as the ESPEN journal, ESPEN consensus
969 papers, the LLL courses and live-expert courses, as well as improved communication
970 between members of the multidisciplinary team. This may be facilitated by the creation of
971 specialty-specific guidelines including a simplified version for community-based care as well
972 as a patient-orientated version.

973

974 **20. Conclusions**

975 These proceedings of the ESPEN Symposium on perioperative care encompass the scientific
976 basis of nutritional and metabolic care in the perioperative period and also suggest areas for
977 future research and change in policy. The main take-home messages are summarized in

978 **Table 4.**

979

980

981 **References**

- 982 [1] Weimann A, Braga M, Carli F, Higashiguchi T, Hubner M, Klek S, et al. ESPEN guideline:
983 Clinical nutrition in surgery. *Clin Nutr* 2017;36:623-50.
- 984 [2] Chernoff R. An overview of tube feeding: From ancient times to the future. *Nutr Clin*
985 *Pract* 2006;21:408-10.
- 986 [3] Dudrick SJ. History of parenteral nutrition. *J Am Coll Nutr* 2009;28:243-51.
- 987 [4] Harkness L. The history of enteral nutrition therapy: From raw eggs and nasal tubes to
988 purified amino acids and early postoperative jejunal delivery. *J Am Diet Assoc* 2002;102:399-
989 404.
- 990 [5] Dukes C. A simple mode of feeding some patients by the nose. *Lancet* 1876;108:394-5.
- 991 [6] Lind J. A treatise of the scurvy. In three parts. Containing an inquiry into the nature,
992 causes, and cure, of that disease, together with a critical and chronological view of what has
993 been published on the subject. Edinburgh: A. Kincaid & A. Donaldson; 1753.
- 994 [7] Mozaffarian D, Rosenberg I, Uauy R. History of modern nutrition science-implications for
995 current research, dietary guidelines, and food policy. *BMJ* 2018;361:k2392.
- 996 [8] Studley HO. Prognosis of weight loss. *JAMA* 1936;106:458-60.
- 997 [9] Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and
998 classification of cancer cachexia: An international consensus. *Lancet Oncol* 2011;12:489-95.
- 999 [10] Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, et al. Sarcopenia
1000 with limited mobility: An international consensus. *J Am Med Dir Assoc* 2011;12:403-9.
- 1001 [11] Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP, et al. ESPEN expert group
1002 recommendations for action against cancer-related malnutrition. *Clin Nutr* 2017;36:1187-96.
- 1003 [12] Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia.
1004 *Nat Rev Dis Primers* 2018;4:17105.
- 1005 [13] Laird B, Fallon M. Treating cancer cachexia: An evolving landscape. *Ann Oncol*
1006 2017;28:2055-6.
- 1007 [14] Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and
1008 treatment effectiveness. *Lancet Oncol* 2014;15:e493-503.
- 1009 [15] Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, et al. ESPEN
1010 guidelines on definitions and terminology of clinical nutrition. *Clin Nutr* 2017;36:49-64.
- 1011 [16] Cederholm T, Jensen GL, Correia M, Gonzalez MC, Fukushima R, Higashiguchi T, et al.
1012 Glim criteria for the diagnosis of malnutrition - a consensus report from the global clinical
1013 nutrition community. *Clin Nutr* 2019;38:1-9.
- 1014 [17] Stratton RJ, Hackston A, Longmore D, Dixon R, Price S, Stroud M, et al. Malnutrition in
1015 hospital outpatients and inpatients: Prevalence, concurrent validity and ease of use of the
1016 'malnutrition universal screening tool' ('MUST') for adults. *Br J Nutr* 2004;92:799-808.
- 1017 [18] Almasaudi AS, McSorley ST, Dolan RD, Edwards CA, McMillan DC. The relation between
1018 malnutrition universal screening tool (MUST), computed tomography-derived body
1019 composition, systemic inflammation, and clinical outcomes in patients undergoing surgery
1020 for colorectal cancer. *Am J Clin Nutr* 2019;110:1327-34.
- 1021 [19] Miller J, Wells L, Nwulu U, Currow D, Johnson MJ, Skipworth RJE. Validated screening
1022 tools for the assessment of cachexia, sarcopenia, and malnutrition: A systematic review. *Am*
1023 *J Clin Nutr* 2018;108:1196-208.
- 1024 [20] Fowler AJ, Abbott TEF, Prowle J, Pearse RM. Age of patients undergoing surgery. *Br J*
1025 *Surg* 2019;106:1012-8.

- 1026 [21] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia:
1027 European consensus on definition and diagnosis: Report of the european working group on
1028 sarcopenia in older people. *Age Ageing* 2010;39:412-23.
- 1029 [22] Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al. Sarcopenia: An
1030 undiagnosed condition in older adults. Current consensus definition: Prevalence, etiology,
1031 and consequences. International working group on sarcopenia. *J Am Med Dir Assoc*
1032 2011;12:249-56.
- 1033 [23] Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia:
1034 Consensus report of the Asian Working Group for Sarcopenia. *J Am Med Dir Assoc*
1035 2014;15:95-101.
- 1036 [24] Dam TT, Peters KW, Fragala M, Cawthon PM, Harris TB, McLean R, et al. An evidence-
1037 based comparison of operational criteria for the presence of sarcopenia. *J Gerontol A Biol Sci*
1038 *Med Sci* 2014;69:584-90.
- 1039 [25] Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G, et al. Consensus
1040 definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by special
1041 interest groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in
1042 geriatrics". *Clin Nutr* 2010;29:154-9.
- 1043 [26] Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in
1044 cancer cachexia. *Nat Rev Clin Oncol* 2013;10:90-9.
- 1045 [27] Ratnayake CB, Loveday BP, Shrikhande SV, Windsor JA, Pandanaboyana S. Impact of
1046 preoperative sarcopenia on postoperative outcomes following pancreatic resection: A
1047 systematic review and meta-analysis. *Pancreatology* 2018;18:996-1004.
- 1048 [28] Kamarajah SK, Bundred J, Tan BHL. Body composition assessment and sarcopenia in
1049 patients with gastric cancer: A systematic review and meta-analysis. *Gastric Cancer*
1050 2019;22:10-22.
- 1051 [29] Matsunaga T, Miyata H, Sugimura K, Motoori M, Asukai K, Yanagimoto Y, et al.
1052 Prognostic significance of sarcopenia and systemic inflammatory response in patients with
1053 esophageal cancer. *Anticancer Res* 2019;39:449-58.
- 1054 [30] Esser H, Resch T, Pamminer M, Mutschlechner B, Troppmair J, Riedmann M, et al.
1055 Preoperative assessment of muscle mass using computerized tomography scans to predict
1056 outcomes following orthotopic liver transplantation. *Transplantation* 2019;103:2506-14.
- 1057 [31] Nakanishi R, Oki E, Sasaki S, Hirose K, Jogo T, Eda Hiro K, et al. Sarcopenia is an
1058 independent predictor of complications after colorectal cancer surgery. *Surg Today*
1059 2018;48:151-7.
- 1060 [32] Mintziras I, Miligkos M, Wachter S, Manoharan J, Maurer E, Bartsch DK. Sarcopenia and
1061 sarcopenic obesity are significantly associated with poorer overall survival in patients with
1062 pancreatic cancer: Systematic review and meta-analysis. *Int J Surg* 2018;59:19-26.
- 1063 [33] Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer
1064 cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor,
1065 independent of body mass index. *J Clin Oncol* 2013;31:1539-47.
- 1066 [34] Dabiri S, Popuri K, Cespedes Feliciano EM, Caan BJ, Baracos VE, Beg MF. Muscle
1067 segmentation in axial computed tomography (CT) images at the lumbar (L3) and thoracic
1068 (T4) levels for body composition analysis. *Comput Med Imaging Graph* 2019;75:47-55.
- 1069 [35] van Dijk DPJ, Bakers FCH, Sanduleanu S, Vaes RDW, Rensen SS, Dejong CHC, et al.
1070 Myosteatosis predicts survival after surgery for periampullary cancer: A novel method using
1071 mri. *HPB (Oxford)* 2018;20:715-20.

- 1072 [36] Ataseven B, Luengo TG, du Bois A, Waltering KU, Traut A, Heitz F, et al. Skeletal muscle
1073 attenuation (sarcopenia) predicts reduced overall survival in patients with advanced
1074 epithelial ovarian cancer undergoing primary debulking surgery. *Ann Surg Oncol*
1075 2018;25:3372-9.
- 1076 [37] Berkel AEM, Klaase JM, de Graaff F, Brusse-Keizer MGJ, Bongers BC, van Meeteren NLU.
1077 Patient's skeletal muscle radiation attenuation and sarcopenic obesity are associated with
1078 postoperative morbidity after neoadjuvant chemoradiation and resection for rectal cancer.
1079 *Dig Surg* 2019;36:376-83.
- 1080 [38] Xiao J, Caan BJ, Weltzien E, Cespedes Feliciano EM, Kroenke CH, Meyerhardt JA, et al.
1081 Associations of pre-existing co-morbidities with skeletal muscle mass and radiodensity in
1082 patients with non-metastatic colorectal cancer. *J Cachexia Sarcopenia Muscle* 2018;9:654-
1083 63.
- 1084 [39] Skipworth RJ, Stewart GD, Dejong CH, Preston T, Fearon KC. Pathophysiology of cancer
1085 cachexia: Much more than host-tumour interaction? *Clin Nutr* 2007;26:667-76.
- 1086 [40] Johns N, Stretch C, Tan BH, Solheim TS, Sorhaug S, Stephens NA, et al. New genetic
1087 signatures associated with cancer cachexia as defined by low skeletal muscle index and
1088 weight loss. *J Cachexia Sarcopenia Muscle* 2017;8:122-30.
- 1089 [41] Bozzetti F, Mariani L, Lo Vullo S, Amerio ML, Biffi R, Caccialanza G, et al. The nutritional
1090 risk in oncology: A study of 1,453 cancer outpatients. *Support Care Cancer* 2012;20:1919-28.
- 1091 [42] Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: A new
1092 definition. *Clin Nutr* 2008;27:793-9.
- 1093 [43] Fearon KC, Voss AC, Hustead DS, Cancer Cachexia Study Group. Definition of cancer
1094 cachexia: Effect of weight loss, reduced food intake, and systemic inflammation on
1095 functional status and prognosis. *Am J Clin Nutr* 2006;83:1345-50.
- 1096 [44] Crossland H, Skirrow S, Puthuchery ZA, Constantin-Teodosiu D, Greenhaff PL. The
1097 impact of immobilisation and inflammation on the regulation of muscle mass and insulin
1098 resistance: Different routes to similar end-points. *J Physiol* 2019;597:1259-70.
- 1099 [45] Galvan E, Arentson-Lantz E, Lamon S, Paddon-Jones D. Protecting skeletal muscle with
1100 protein and amino acid during periods of disuse. *Nutrients* 2016;8.
- 1101 [46] Deutz NE, Pereira SL, Hays NP, Oliver JS, Edens NK, Evans CM, et al. Effect of beta-
1102 hydroxy-beta-methylbutyrate (HMB) on lean body mass during 10 days of bed rest in older
1103 adults. *Clin Nutr* 2013;32:704-12.
- 1104 [47] Drummond MJ, Dickinson JM, Fry CS, Walker DK, Gundermann DM, Reidy PT, et al. Bed
1105 rest impairs skeletal muscle amino acid transporter expression, mtorc1 signaling, and
1106 protein synthesis in response to essential amino acids in older adults. *Am J Physiol*
1107 *Endocrinol Metab* 2012;302:E1113-22.
- 1108 [48] Hvid LG, Suetta C, Nielsen JH, Jensen MM, Frandsen U, Ortenblad N, et al. Aging impairs
1109 the recovery in mechanical muscle function following 4 days of disuse. *Exp Gerontol*
1110 2014;52:1-8.
- 1111 [49] Ferrando AA, Tipton KD, Bammann MM, Wolfe RR. Resistance exercise maintains skeletal
1112 muscle protein synthesis during bed rest. *J Appl Physiol* (1985) 1997;82:807-10.
- 1113 [50] Bos C, Benamouzig R, Bruhat A, Roux C, Valensi P, Ferriere F, et al. Nutritional status
1114 after short-term dietary supplementation in hospitalized malnourished geriatric patients.
1115 *Clin Nutr* 2001;20:225-33.
- 1116 [51] Ferrando AA, Paddon-Jones D, Hays NP, Kortebein P, Ronsen O, Williams RH, et al. EAA
1117 supplementation to increase nitrogen intake improves muscle function during bed rest in the
1118 elderly. *Clin Nutr* 2010;29:18-23.

- 1119 [52] Paddon-Jones D, Sheffield-Moore M, Urban RJ, Sanford AP, Aarsland A, Wolfe RR, et al.
1120 Essential amino acid and carbohydrate supplementation ameliorates muscle protein loss in
1121 humans during 28 days bedrest. *J Clin Endocrinol Metab* 2004;89:4351-8.
- 1122 [53] Puthuchery ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, et al. Acute
1123 skeletal muscle wasting in critical illness. *JAMA* 2013;310:1591-600.
- 1124 [54] Williams JP, Phillips BE, Smith K, Atherton PJ, Rankin D, Selby AL, et al. Effect of tumor
1125 burden and subsequent surgical resection on skeletal muscle mass and protein turnover in
1126 colorectal cancer patients. *Am J Clin Nutr* 2012;96:1064-70.
- 1127 [55] Schindler K, Pichard C, Sulz I, Volkert D, Streicher M, Singer P, et al. nutritionDay: 10
1128 years of growth. *Clin Nutr* 2017;36:1207-14.
- 1129 [56] Frantal S, Pernicka E, Hiesmayr M, Schindler K, Bauer P. Length bias correction in one-
1130 day cross-sectional assessments - the nutritionday study. *Clin Nutr* 2016;35:522-7.
- 1131 [57] Pirlich M, Schutz T, Norman K, Gastell S, Lubke HJ, Bischoff SC, et al. The German
1132 hospital malnutrition study. *Clin Nutr* 2006;25:563-72.
- 1133 [58] Pikul J, Sharpe MD, Lowndes R, Ghent CN. Degree of preoperative malnutrition is
1134 predictive of postoperative morbidity and mortality in liver transplant recipients.
1135 *Transplantation* 1994;57:469-72.
- 1136 [59] Meguid MM, Debonis D, Meguid V, Hill LR, Terz JJ. Complications of abdominal
1137 operations for malignant disease. *Am J Surg* 1988;156:341-5.
- 1138 [60] Kondrup J, Allison SP, Elia M, Vellas B, Plauth M, Educational, et al. ESPEN guidelines for
1139 nutrition screening 2002. *Clin Nutr* 2003;22:415-21.
- 1140 [61] Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. Perioperative total
1141 parenteral nutrition in surgical patients. *N Engl J Med* 1991;325:525-32.
- 1142 [62] Detsky AS, McLaughlin JR, Baker JP, Johnston N, Whittaker S, Mendelson RA, et al. What
1143 is subjective global assessment of nutritional status? *JPEN J Parenter Enteral Nutr* 1987;11:8-
1144 13.
- 1145 [63] Cohendy R, Rubenstein LZ, Eledjam JJ. The mini nutritional assessment-short form for
1146 preoperative nutritional evaluation of elderly patients. *Aging (Milano)* 2001;13:293-7.
- 1147 [64] Kondrup J, Rasmussen HH, Hamberg O, Stanga Z, Ad Hoc EWG. Nutritional risk screening
1148 (NRS 2002): A new method based on an analysis of controlled clinical trials. *Clin Nutr*
1149 2003;22:321-36.
- 1150 [65] Guo W, Ou G, Li X, Huang J, Liu J, Wei H. Screening of the nutritional risk of patients with
1151 gastric carcinoma before operation by NRS 2002 and its relationship with postoperative
1152 results. *J Gastroenterol Hepatol* 2010;25:800-3.
- 1153 [66] Schwegler I, von Holzen A, Gutzwiller JP, Schlumpf R, Muhlebach S, Stanga Z. Nutritional
1154 risk is a clinical predictor of postoperative mortality and morbidity in surgery for colorectal
1155 cancer. *Br J Surg* 2010;97:92-7.
- 1156 [67] Schiesser M, Muller S, Kirchhoff P, Breitenstein S, Schafer M, Clavien PA. Assessment of
1157 a novel screening score for nutritional risk in predicting complications in gastro-intestinal
1158 surgery. *Clin Nutr* 2008;27:565-70.
- 1159 [68] Schiesser M, Kirchhoff P, Muller MK, Schafer M, Clavien PA. The correlation of nutrition
1160 risk index, nutrition risk score, and bioimpedance analysis with postoperative complications
1161 in patients undergoing gastrointestinal surgery. *Surgery* 2009;145:519-26.
- 1162 [69] Sun Z, Kong XJ, Jing X, Deng RJ, Tian ZB. Nutritional risk screening 2002 as a predictor of
1163 postoperative outcomes in patients undergoing abdominal surgery: A systematic review and
1164 meta-analysis of prospective cohort studies. *PLoS One* 2015;10:e0132857.

- 1165 [70] Reber E, Gomes F, Vasiloglou MF, Schuetz P, Stanga Z. Nutritional risk screening and
1166 assessment. *J Clin Med* 2019;8.
- 1167 [71] Fearon KC, Ljungqvist O, Von Meyenfeldt M, Revhaug A, Dejong CH, Lassen K, et al.
1168 Enhanced Recovery After Surgery: A consensus review of clinical care for patients
1169 undergoing colonic resection. *Clin Nutr* 2005;24:466-77.
- 1170 [72] Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative
1171 period to improve long-term cancer outcomes. *Nat Rev Clin Oncol* 2015;12:213-26.
- 1172 [73] Allison SP. The uses and limitations of nutritional support the arvid wretlind lecture
1173 given at the 14th ESPEN Congress in Vienna, 1992. *Clin Nutr* 1992;11:319-30.
- 1174 [74] Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN
1175 guidelines on nutrition in cancer patients. *Clin Nutr* 2017;36:11-48.
- 1176 [75] Gould DW, Lahart I, Carmichael AR, Koutedakis Y, Metsios GS. Cancer cachexia
1177 prevention via physical exercise: Molecular mechanisms. *J Cachexia Sarcopenia Muscle*
1178 2013;4:111-24.
- 1179 [76] Bauer J, Biolo G, Cederholm T, Cesari M, Cruz-Jentoft AJ, Morley JE, et al. Evidence-
1180 based recommendations for optimal dietary protein intake in older people: A position paper
1181 from the prot-age study group. *J Am Med Dir Assoc* 2013;14:542-59.
- 1182 [77] Elia M, Normand C, Norman K, Laviano A. A systematic review of the cost and cost
1183 effectiveness of using standard oral nutritional supplements in the hospital setting. *Clin Nutr*
1184 2016;35:370-80.
- 1185 [78] Fukuda Y, Yamamoto K, Hirao M, Nishikawa K, Maeda S, Haraguchi N, et al. Prevalence
1186 of malnutrition among gastric cancer patients undergoing gastrectomy and optimal
1187 preoperative nutritional support for preventing surgical site infections. *Ann Surg Oncol*
1188 2015;22 Suppl 3:S778-85.
- 1189 [79] Awad S, Varadhan KK, Ljungqvist O, Lobo DN. A meta-analysis of randomised controlled
1190 trials on preoperative oral carbohydrate treatment in elective surgery. *Clin Nutr* 2013;32:34-
1191 44.
- 1192 [80] Amer MA, Smith MD, Herbison GP, Plank LD, McCall JL. Network meta-analysis of the
1193 effect of preoperative carbohydrate loading on recovery after elective surgery. *Br J Surg*
1194 2017;104:187-97.
- 1195 [81] Gianotti L, Biffi R, Sandini M, Marrelli D, Vignali A, Caccialanza R, et al. Preoperative oral
1196 carbohydrate load versus placebo in major elective abdominal surgery (PROCY): A
1197 randomized, placebo-controlled, multicenter, phase III trial. *Ann Surg* 2018;267:623-30.
- 1198 [82] Minnella EM, Bousquet-Dion G, Awasthi R, Scheede-Bergdahl C, Carli F. Multimodal
1199 prehabilitation improves functional capacity before and after colorectal surgery for cancer: A
1200 five-year research experience. *Acta Oncol* 2017;56:295-300.
- 1201 [83] Gillis C, Buhler K, Bresee L, Carli F, Gramlich L, Culos-Reed N, et al. Effects of nutritional
1202 prehabilitation, with and without exercise, on outcomes of patients who undergo colorectal
1203 surgery: A systematic review and meta-analysis. *Gastroenterology* 2018;155:391-410 e4.
- 1204 [84] Gillis C, Fenton TR, Sajobi TT, Minnella EM, Awasthi R, Loiselle SE, et al. Trimodal
1205 prehabilitation for colorectal surgery attenuates post-surgical losses in lean body mass: A
1206 pooled analysis of randomized controlled trials. *Clin Nutr* 2019;38:1053-60.
- 1207 [85] Dunne DF, Jack S, Jones RP, Jones L, Lythgoe DT, Malik HZ, et al. Randomized clinical trial
1208 of prehabilitation before planned liver resection. *Br J Surg* 2016;103:504-12.
- 1209 [86] Yamamoto K, Nagatsuma Y, Fukuda Y, Hirao M, Nishikawa K, Miyamoto A, et al.
1210 Effectiveness of a preoperative exercise and nutritional support program for elderly
1211 sarcopenic patients with gastric cancer. *Gastric Cancer* 2017;20:913-8.

- 1212 [87] Barberan-Garcia A, Ubre M, Roca J, Lacy AM, Burgos F, Risco R, et al. Personalised
1213 prehabilitation in high-risk patients undergoing elective major abdominal surgery: A
1214 randomized blinded controlled trial. *Ann Surg* 2018;267:50-6.
- 1215 [88] Dhatariya K FD, Hilton L, Kilvert A, Levy N, Rayman G, Watson B. Management of adults
1216 with diabetes undergoing surgery and elective procedures: Improving standards. London:
1217 Diabetes UK; 2011. Available at: [http://www.diabetologists-
1218 abcd.org.uk/JBDS/JBDS_IP_Surgery_Adults_Full.pdf](http://www.diabetologists-abcd.org.uk/JBDS/JBDS_IP_Surgery_Adults_Full.pdf) (Accessed 10 March 2020).
- 1219 [89] Pournaras DJ, Photi ES, Barnett N, Challand CP, Chatzizacharias NA, Dlamini NP, et al.
1220 Assessing the quality of primary care referrals to surgery of patients with diabetes in the east
1221 of england: A multi-centre cross-sectional cohort study. *Int J Clin Pract* 2017;71:e12971.
- 1222 [90] Frisch A, Chandra P, Smiley D, Peng L, Rizzo M, Gatcliffe C, et al. Prevalence and clinical
1223 outcome of hyperglycemia in the perioperative period in noncardiac surgery. *Diabetes Care*
1224 2010;33:1783-8.
- 1225 [91] Kotagal M, Symons RG, Hirsch IB, Umpierrez GE, Dellinger EP, Farrokhi ET, et al.
1226 Perioperative hyperglycemia and risk of adverse events among patients with and without
1227 diabetes. *Ann Surg* 2015;261:97-103.
- 1228 [92] Kwon S, Thompson R, Dellinger P, Yanez D, Farrohki E, Flum D. Importance of
1229 perioperative glycemic control in general surgery: A report from the surgical care and
1230 outcomes assessment program. *Ann Surg* 2013;257:8-14.
- 1231 [93] Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG. Glycemic control and
1232 risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort
1233 study. *Diabetes Care* 2018;41:2127-35.
- 1234 [94] Jones CE, Graham LA, Morris MS, Richman JS, Hollis RH, Wahl TS, et al. Association
1235 between preoperative hemoglobin A1c levels, postoperative hyperglycemia, and
1236 readmissions following gastrointestinal surgery. *JAMA Surg* 2017;152:1031-8.
- 1237 [95] National Collaborating Centre for Acute Care (UK). Preoperative Tests. The Use of
1238 Routine Preoperative Tests for Elective Surgery. London: National Collaborating Centre for
1239 Acute Care (UK); 2003. Available at:
1240 https://www.ncbi.nlm.nih.gov/books/NBK48489/pdf/Bookshelf_NBK48489.pdf (Accessed 10
1241 March 2020).
- 1242 [96] Dhatariya KK, Wiles MD. Pre-operative testing guidelines: A NICE try but not enough.
1243 *Anaesthesia* 2016;71:1403-7.
- 1244 [97] Lobo DN. Fluid, electrolytes and nutrition: Physiological and clinical aspects. *Proc Nutr*
1245 *Soc* 2004;63:453-66.
- 1246 [98] Keys A, Brozek J, Henschel A, Mickelsen O, Taylor HF. The biology of human starvation.
1247 Minneapolis: University of Minnesota Press; 1950.
- 1248 [99] Moore FD. Metabolic care of the surgical patient. Philadelphia: W. B. Saunders; 1959.
- 1249 [100] Shizgal HM. The effect of malnutrition on body composition. *Surg Gynecol Obstet*
1250 1981;152:22-6.
- 1251 [101] Winick M. Hunger disease: Studies by the jewish physicians in the warsaw ghetto. New
1252 York: Wiley; 1979.
- 1253 [102] Wilkinson AW, Billing BH, et al. Excretion of chloride and sodium after surgical
1254 operations. *Lancet* 1949;1:640-4.
- 1255 [103] Wilkinson AW, Billing BH, Nagy G, Stewart CP. Excretion of potassium after partial
1256 gastrectomy. *Lancet* 1950;2:135-7.
- 1257 [104] Thiele RH, Raghunathan K, Brudney CS, Lobo DN, Martin D, Senagore A, et al. American
1258 Society for Enhanced Recovery (ASER) and Perioperative Quality Initiative (POQI) joint

- 1259 consensus statement on perioperative fluid management within an enhanced recovery
1260 pathway for colorectal surgery. *Perioper Med (Lond)* 2016;5:24.
- 1261 [105] Gan TJ, Soppitt A, Maroof M, el-Moalem H, Robertson KM, Moretti E, et al. Goal-
1262 directed intraoperative fluid administration reduces length of hospital stay after major
1263 surgery. *Anesthesiology* 2002;97:820-6.
- 1264 [106] Noblett SE, Snowden CP, Shenton BK, Horgan AF. Randomized clinical trial assessing
1265 the effect of Doppler-optimized fluid management on outcome after elective colorectal
1266 resection. *Br J Surg* 2006;93:1069-76.
- 1267 [107] Feldheiser A, Aziz O, Baldini G, Cox BP, Fearon KC, Feldman LS, et al. Enhanced
1268 Recovery After Surgery (ERAS) for gastrointestinal surgery, part 2: Consensus statement for
1269 anaesthesia practice. *Acta Anaesthesiol Scand* 2016;60:289-334.
- 1270 [108] Rollins KE, Lobo DN. Intraoperative goal-directed fluid therapy in elective major
1271 abdominal surgery: A meta-analysis of randomized controlled trials. *Ann Surg* 2016;263:465-
1272 76.
- 1273 [109] Rollins KE, Mathias NC, Lobo DN. Meta-analysis of goal-directed fluid therapy using
1274 transoesophageal Doppler monitoring in patients undergoing elective colorectal surgery. *BJS*
1275 *Open* 2019;3:606-16.
- 1276 [110] Lassen K, Kjaeve J, Fetveit T, Trano G, Sigurdsson HK, Horn A, et al. Allowing normal
1277 food at will after major upper gastrointestinal surgery does not increase morbidity: A
1278 randomized multicenter trial. *Ann Surg* 2008;247:721-9.
- 1279 [111] Zhuang CL, Ye XZ, Zhang CJ, Dong QT, Chen BC, Yu Z. Early versus traditional
1280 postoperative oral feeding in patients undergoing elective colorectal surgery: A meta-
1281 analysis of randomized clinical trials. *Dig Surg* 2013;30:225-32.
- 1282 [112] NICE Guideline [CG174]. Intravenous fluid therapy for adults in hospital. London:
1283 National Institute for Health and Care Excellence; 2013. Available at:
1284 <https://www.nice.org.uk/guidance/cg174> (Accessed 10 March 2020).
- 1285 [113] Lobo DN, Bostock KA, Neal KR, Perkins AC, Rowlands BJ, Allison SP. Effect of salt and
1286 water balance on recovery of gastrointestinal function after elective colonic resection: A
1287 randomised controlled trial. *Lancet* 2002;359:1812-8.
- 1288 [114] Van Regenmortel N, De Weerd T, Van Craenenbroeck AH, Roelant E, Verbrugghe W,
1289 Dams K, et al. Effect of isotonic versus hypotonic maintenance fluid therapy on urine output,
1290 fluid balance, and electrolyte homeostasis: A crossover study in fasting adult volunteers. *Br J*
1291 *Anaesth* 2017;118:892-900.
- 1292 [115] Gould TH, Grace K, Thorne G, Thomas M. Effect of thoracic epidural anaesthesia on
1293 colonic blood flow. *Br J Anaesth* 2002;89:446-51.
- 1294 [116] Holte K, Foss NB, Svensen C, Lund C, Madsen JL, Kehlet H. Epidural anesthesia,
1295 hypotension, and changes in intravascular volume. *Anesthesiology* 2004;100:281-6.
- 1296 [117] Lobo DN. Fluid overload and surgical outcome: Another piece in the jigsaw. *Ann Surg*
1297 2009;249:186-8.
- 1298 [118] Shin CH, Long DR, McLean D, Grabitz SD, Ladha K, Timm FP, et al. Effects of
1299 intraoperative fluid management on postoperative outcomes: A hospital registry study. *Ann*
1300 *Surg* 2018;267:1084-92.
- 1301 [119] Thacker JK, Mountford WK, Ernst FR, Krukas MR, Mythen MM. Perioperative fluid
1302 utilization variability and association with outcomes: Considerations for enhanced recovery
1303 efforts in sample US surgical populations. *Ann Surg* 2016;263:502-10.

- 1304 [120] Varadhan KK, Lobo DN. A meta-analysis of randomised controlled trials of intravenous
1305 fluid therapy in major elective open abdominal surgery: Getting the balance right. *Proc Nutr*
1306 *Soc* 2010;69:488-98.
- 1307 [121] Lobo DN, Stanga Z, Aloysius MM, Wicks C, Nunes QM, Ingram KL, et al. Effect of
1308 volume loading with 1 liter intravenous infusions of 0.9% saline, 4% succinylated gelatine
1309 (gelofusine) and 6% hydroxyethyl starch (voluven) on blood volume and endocrine
1310 responses: A randomized, three-way crossover study in healthy volunteers. *Crit Care Med*
1311 2010;38:464-70.
- 1312 [122] Drummer C, Gerzer R, Heer M, Molz B, Bie P, Schlossberger M, et al. Effects of an acute
1313 saline infusion on fluid and electrolyte metabolism in humans. *Am J Physiol* 1992;262:F744-
1314 54.
- 1315 [123] Lobo DN, Stanga Z, Simpson JA, Anderson JA, Rowlands BJ, Allison SP. Dilution and
1316 redistribution effects of rapid 2-litre infusions of 0.9% (w/v) saline and 5% (w/v) dextrose on
1317 haematological parameters and serum biochemistry in normal subjects: A double-blind
1318 crossover study. *Clin Sci (Lond)* 2001;101:173-9.
- 1319 [124] Reid F, Lobo DN, Williams RN, Rowlands BJ, Allison SP. (ab)normal saline and
1320 physiological Hartmann's solution: A randomized double-blind crossover study. *Clin Sci*
1321 *(Lond)* 2003;104:17-24.
- 1322 [125] Wilkes NJ, Woolf R, Mutch M, Mallett SV, Peachey T, Stephens R, et al. The effects of
1323 balanced versus saline-based hetastarch and crystalloid solutions on acid-base and
1324 electrolyte status and gastric mucosal perfusion in elderly surgical patients. *Anesth Analg*
1325 2001;93:811-6.
- 1326 [126] Williams EL, Hildebrand KL, McCormick SA, Bedel MJ. The effect of intravenous
1327 lactated ringer's solution versus 0.9% sodium chloride solution on serum osmolality in
1328 human volunteers [see comments]. *Anesth Analg* 1999;88:999-1003.
- 1329 [127] Chowdhury AH, Lobo DN. Fluids and gastrointestinal function. *Curr Opin Clin Nutr*
1330 *Metab Care* 2011;14:469-76.
- 1331 [128] Lobo DN, Allison SP. Fluid, electrolyte and nutrient replacement. In: Burnand KG,
1332 Young AE, Lucas J, Rowlands BJ, Scholefield J, editors. *The new Aird's companion in surgical*
1333 *studies*. 3rd ed. London: Churchill Livingstone; 2005. p. 20-41.
- 1334 [129] Friedman J, Lussiez A, Sullivan J, Wang S, Englesbe M. Implications of sarcopenia in
1335 major surgery. *Nutr Clin Pract* 2015;30:175-9.
- 1336 [130] Muckart DJ, Bhagwanjee S. American College of Chest Physicians/Society of Critical
1337 Care Medicine Consensus Conference definitions of the systemic inflammatory response
1338 syndrome and allied disorders in relation to critically injured patients. *Crit Care Med*
1339 1997;25:1789-95.
- 1340 [131] Gabay C, Kushner I. Acute-phase proteins and other systemic responses to
1341 inflammation. *N Engl J Med* 1999;340:448-54.
- 1342 [132] Watt DG, Horgan PG, McMillan DC. Routine clinical markers of the magnitude of the
1343 systemic inflammatory response after elective operation: A systematic review. *Surgery*
1344 2015;157:362-80.
- 1345 [133] Platt JJ, Ramanathan ML, Crosbie RA, Anderson JH, McKee RF, Horgan PG, et al. C-
1346 reactive protein as a predictor of postoperative infective complications after curative
1347 resection in patients with colorectal cancer. *Ann Surg Oncol* 2012;19:4168-77.
- 1348 [134] Gans SL, Atema JJ, van Dieren S, Groot Koerkamp B, Boermeester MA. Diagnostic value
1349 of c-reactive protein to rule out infectious complications after major abdominal surgery: A
1350 systematic review and meta-analysis. *Int J Colorectal Dis* 2015;30:861-73.

- 1351 [135] Straatman J, Harmsen AM, Cuesta MA, Berkhof J, Jansma EP, van der Peet DL.
1352 Predictive value of c-reactive protein for major complications after major abdominal surgery:
1353 A systematic review and pooled-analysis. *PLoS One* 2015;10:e0132995.
- 1354 [136] Watt DG, McSorley ST, Horgan PG, McMillan DC. Enhanced recovery after surgery:
1355 Which components, if any, impact on the systemic inflammatory response following
1356 colorectal surgery?: A systematic review. *Medicine (Baltimore)* 2015;94:e1286.
- 1357 [137] McSorley ST, Horgan PG, McMillan DC. The impact of preoperative corticosteroids on
1358 the systemic inflammatory response and postoperative complications following surgery for
1359 gastrointestinal cancer: A systematic review and meta-analysis. *Crit Rev Oncol Hematol*
1360 2016;101:139-50.
- 1361 [138] Golder AM, Steele CW, Conn D, MacKay GJ, McMillan DC, Horgan PG, et al. Effect of
1362 preoperative oral antibiotics in combination with mechanical bowel preparation on
1363 inflammatory response and short-term outcomes following left-sided colonic and rectal
1364 resections. *BJS Open* 2019;3:830-9.
- 1365 [139] Rollins KE, Javanmard-Emamghissi H, Acheson AG, Lobo DN. The role of oral antibiotic
1366 preparation in elective colorectal surgery: A meta-analysis. *Ann Surg* 2019;270:43-58.
- 1367 [140] Ljungqvist O, Scott M, Fearon KC. Enhanced Recovery After Surgery: A review. *JAMA*
1368 *Surg* 2017;152:292-8.
- 1369 [141] Rollins KE, Javanmard-Emamghissi H, Lobo DN. Impact of mechanical bowel
1370 preparation in elective colorectal surgery: A meta-analysis. *World J Gastroenterol*
1371 2018;24:519-36.
- 1372 [142] Maessen J, Dejong CH, Hausel J, Nygren J, Lassen K, Andersen J, et al. A protocol is not
1373 enough to implement an enhanced recovery programme for colorectal resection. *Br J Surg*
1374 2007;94:224-31.
- 1375 [143] Varadhan KK, Neal KR, Dejong CH, Fearon KC, Ljungqvist O, Lobo DN. The enhanced
1376 recovery after surgery (ERAS) pathway for patients undergoing major elective open
1377 colorectal surgery: A meta-analysis of randomized controlled trials. *Clin Nutr* 2010;29:434-
1378 40.
- 1379 [144] Visoni A, Shah R, Gabriel E, Attwood K, Kukar M, Nurkin S. Enhanced recovery after
1380 surgery for noncolorectal surgery?: A systematic review and meta-analysis of major
1381 abdominal surgery. *Ann Surg* 2018;267:57-65.
- 1382 [145] Jia Y, Jin G, Guo S, Gu B, Jin Z, Gao X, et al. Fast-track surgery decreases the incidence
1383 of postoperative delirium and other complications in elderly patients with colorectal
1384 carcinoma. *Langenbecks Arch Surg* 2014;399:77-84.
- 1385 [146] Jorgensen CC, Madsbad S, Kehlet H, Lundbeck Foundation Centre for Fast-track H,
1386 Knee Replacement Collaborative G. Postoperative morbidity and mortality in type-2
1387 diabetics after fast-track primary total hip and knee arthroplasty. *Anesth Analg*
1388 2015;120:230-8.
- 1389 [147] Hendry PO, Hausel J, Nygren J, Lassen K, Dejong CH, Ljungqvist O, et al. Determinants
1390 of outcome after colorectal resection within an enhanced recovery programme. *Br J Surg*
1391 2009;96:197-205.
- 1392 [148] Gianotti L, Sandini M, Romagnoli S, Carli F, Ljungqvist O. Enhanced recovery programs
1393 in gastrointestinal surgery: Actions to promote optimal perioperative nutritional and
1394 metabolic care. *Clin Nutr* 2019 [Epub ahead of print] doi: 10.1016/j.clnu.2019.10.023.
- 1395 [149] Pedziwiatr M, Pisarska M, Kisielewski M, Matlok M, Major P, Wierdak M, et al. Is ERAS
1396 in laparoscopic surgery for colorectal cancer changing risk factors for delayed recovery? *Med*
1397 *Oncol* 2016;33:25.

- 1398 [150] Ljungqvist O, Jonathan E, Rhoads lecture 2011: Insulin resistance and enhanced
1399 recovery after surgery. *JPEN J Parenter Enteral Nutr* 2012;36:389-98.
- 1400 [151] Gustafsson UO, Hausel J, Thorell A, Ljungqvist O, Soop M, Nygren J, et al. Adherence to
1401 the enhanced recovery after surgery protocol and outcomes after colorectal cancer surgery.
1402 *Arch Surg* 2011;146:571-7.
- 1403 [152] ERAS Compliance Group. The impact of enhanced recovery protocol compliance on
1404 elective colorectal cancer resection: Results from an international registry. *Ann Surg*
1405 2015;261:1153-9.
- 1406 [153] Gustafsson UO, Opperstrup H, Thorell A, Nygren J, Ljungqvist O. Adherence to the eras
1407 protocol is associated with 5-year survival after colorectal cancer surgery: A retrospective
1408 cohort study. *World J Surg* 2016;40:1741-7.
- 1409 [154] The Lancet Commission on Global Surgery. <https://www.lancetglobalsurgery.org>. 2016.
1410 (Accessed 10 March 2020).
- 1411 [155] Nationella Kvalitetsregister.
1412 [Http://www.kvalitetsregister.se/hittaregister/registerarkiv/tjockochandtarmscancer.2315.H](http://www.kvalitetsregister.se/hittaregister/registerarkiv/tjockochandtarmscancer.2315.html)
1413 [tml](http://www.kvalitetsregister.se/hittaregister/registerarkiv/tjockochandtarmscancer.2315.html).
- 1414 [156] Healy MA, Regenbogen SE, Kanters AE, Suwanabol PA, Varban OA, Campbell DA, Jr., et
1415 al. Surgeon variation in complications with minimally invasive and open colectomy: Results
1416 from the michigan surgical quality collaborative. *JAMA Surg* 2017;152:860-7.
- 1417 [157] Lilot M, Ehrenfeld JM, Lee C, Harrington B, Cannesson M, Rinehart J. Variability in
1418 practice and factors predictive of total crystalloid administration during abdominal surgery:
1419 Retrospective two-centre analysis. *Br J Anaesth* 2015;114:767-76.
- 1420 [158] Ljungqvist O, Thanh NX, Nelson G. ERAS-value based surgery. *J Surg Oncol*
1421 2017;116:608-12.
- 1422 [159] Burch J, Taylor C. Patients' need for nursing telephone follow-up after enhanced
1423 recovery. *Gastrointestinal Nursing* 2012;10:51-8.
- 1424 [160] McShane C, Honeysett A. What is the preadmission role in preparation of patients for
1425 fast track surgery? *Aust Nurs J* 2013;20:37-9.
- 1426 [161] Gerritsen A, Besselink MG, Gouma DJ, Steenhagen E, Borel Rinkes IH, Molenaar IQ.
1427 Systematic review of five feeding routes after pancreatoduodenectomy. *Br J Surg*
1428 2013;100:589-98; discussion 99.
- 1429 [162] Adiamah A, Ranat R, Gomez D. Enteral versus parenteral nutrition following
1430 pancreaticoduodenectomy: A systematic review and meta-analysis. *HPB (Oxford)*
1431 2019;21:793-801.
- 1432 [163] Lee SH, Jang JY, Kim HW, Jung MJ, Lee JG. Effects of early enteral nutrition on patients
1433 after emergency gastrointestinal surgery: A propensity score matching analysis. *Medicine*
1434 (Baltimore) 2014;93:e323.
- 1435 [164] Andersen HK, Lewis SJ, Thomas S. Early enteral nutrition within 24h of colorectal
1436 surgery versus later commencement of feeding for postoperative complications. *Cochrane*
1437 *Database Syst Rev* 2006;4:CD004080.
- 1438 [165] Herbert G, Perry R, Andersen HK, Atkinson C, Penfold C, Lewis SJ, et al. Early enteral
1439 nutrition within 24 hours of lower gastrointestinal surgery versus later commencement for
1440 length of hospital stay and postoperative complications. *Cochrane Database Syst Rev*
1441 2018;10:CD004080.
- 1442 [166] Willcutts KF, Chung MC, Erenberg CL, Finn KL, Schirmer BD, Byham-Gray LD. Early oral
1443 feeding as compared with traditional timing of oral feeding after upper gastrointestinal
1444 surgery: A systematic review and meta-analysis. *Ann Surg* 2016;264:54-63.

- 1445 [167] Christensen T, Kehlet H. Postoperative fatigue and changes in nutritional status. *Br J*
1446 *Surg* 1984;71:473-6.
- 1447 [168] Latimer LE, Constantin D, Greening NJ, Calvert L, Menon MK, Steiner MC, et al. Impact
1448 of transcutaneous neuromuscular electrical stimulation or resistance exercise on skeletal
1449 muscle mRNA expression in COPD. *Int J Chron Obstruct Pulmon Dis* 2019;14:1355-64.
- 1450 [169] Suetta C, Hvid LG, Justesen L, Christensen U, Neergaard K, Simonsen L, et al. Effects of
1451 aging on human skeletal muscle after immobilization and retraining. *J Appl Physiol* (1985)
1452 2009;107:1172-80.
- 1453 [170] Constantin D, Menon MK, Houchen-Wolloff L, Morgan MD, Singh SJ, Greenhaff P, et al.
1454 Skeletal muscle molecular responses to resistance training and dietary supplementation in
1455 COPD. *Thorax* 2013;68:625-33.
- 1456 [171] Soeters PB, Grecu I. Have we enough glutamine and how does it work? A clinician's
1457 view. *Ann Nutr Metab* 2012;60:17-26.
- 1458 [172] Petersson B, Vinnars E, Waller SO, Wernerman J. Long-term changes in muscle free
1459 amino acid levels after elective abdominal surgery. *Br J Surg* 1992;79:212-6.
- 1460 [173] Souba WW, Klimberg VS, Plumley DA, Salloum RM, Flynn TC, Bland KI, et al. The role of
1461 glutamine in maintaining a healthy gut and supporting the metabolic response to injury and
1462 infection. *J Surg Res* 1990;48:383-91.
- 1463 [174] Zheng Y, Li F, Qi B, Luo B, Sun H, Liu S, et al. Application of perioperative
1464 immunonutrition for gastrointestinal surgery: A meta-analysis of randomized controlled
1465 trials. *Asia Pac J Clin Nutr* 2007;16 Suppl 1:253-7.
- 1466 [175] Gianotti L, Braga M, Biffi R, Bozzetti F, Mariani L; GlutamItaly Research Group of the
1467 Italian Society of Parenteral, and Enteral Nutrition. Perioperative intravenous glutamine
1468 supplementation in major abdominal surgery for cancer: A randomized multicenter trial. *Ann*
1469 *Surg* 2009;250:684-90.
- 1470 [176] Ziegler TR, May AK, Hebbard G, Easley KA, Griffith DP, Dave N, et al. Efficacy and safety
1471 of glutamine-supplemented parenteral nutrition in surgical ICU patients: An American
1472 multicenter randomized controlled trial. *Ann Surg* 2016;263:646-55.
- 1473 [177] Sandini M, Nespoli L, Oldani M, Bernasconi DP, Gianotti L. Effect of glutamine
1474 dipeptide supplementation on primary outcomes for elective major surgery: Systematic
1475 review and meta-analysis. *Nutrients* 2015;7:481-99.
- 1476 [178] Mayer K, Seeger W, Grimminger F. Clinical use of lipids to control inflammatory
1477 disease. *Curr Opin Clin Nutr Metab Care* 1998;1:179-84.
- 1478 [179] Wichmann MW, Thul P, Czarnetzki HD, Morlion BJ, Kemen M, Jauch KW. Evaluation of
1479 clinical safety and beneficial effects of a fish oil containing lipid emulsion (Lipoplus, MLF541):
1480 Data from a prospective, randomized, multicenter trial. *Crit Care Med* 2007;35:700-6.
- 1481 [180] Pradelli L, Mayer K, Klek S, Omar Alsaleh AJ, Clark RAC, Rosenthal MD, et al. Omega-3
1482 fatty-acid enriched parenteral nutrition in hospitalized patients: Systematic review with
1483 meta-analysis and trial sequential analysis. *JPEN J Parenter Enteral Nutr* 2020;44:44-57.
- 1484 [181] Li NN, Zhou Y, Qin XP, Chen Y, He D, Feng JY, et al. Does intravenous fish oil benefit
1485 patients post-surgery? A meta-analysis of randomised controlled trials. *Clin Nutr*
1486 2014;33:226-39.
- 1487 [182] Adiamah A, Skorepa P, Weimann A, Lobo DN. The impact of preoperative immune
1488 modulating nutrition on outcomes in patients undergoing surgery for gastrointestinal
1489 cancer: A systematic review and meta-analysis. *Ann Surg* 2019;270:247-56.

- 1490 [183] Marimuthu K, Varadhan KK, Ljungqvist O, Lobo DN. A meta-analysis of the effect of
1491 combinations of immune modulating nutrients on outcome in patients undergoing major
1492 open gastrointestinal surgery. *Ann Surg* 2012;255:1060-8.
- 1493 [184] Moya P, Miranda E, Soriano-Irigaray L, Arroyo A, Aguilar MD, Bellon M, et al.
1494 Perioperative immunonutrition in normo-nourished patients undergoing laparoscopic
1495 colorectal resection. *Surg Endosc* 2016;30:4946-53.
- 1496 [185] WHO/FAO. Health and Nutritional Properties of Probiotics in Food Including Powder
1497 Milk with Live Lactic Acid Bacteria; Report of a Joint FAO/WHO Expert Consultation on
1498 Evaluation of health and Nutritional Properties of Probiotics in Food Including Powder Milk
1499 with Live Lactic Acid Bacteria. Rome: Food and Agriculture Organization of the United
1500 Nations, World Health Organization; 2001.
- 1501 [186] Slavin J. Fiber and prebiotics: Mechanisms and health benefits. *Nutrients* 2013;5:1417-
1502 35.
- 1503 [187] Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious
1504 diarrhoea. *Cochrane Database Syst Rev* 2010;11:CD003048.
- 1505 [188] Huang JS, Bousvaros A, Lee JW, Diaz A, Davidson EJ. Efficacy of probiotic use in acute
1506 diarrhea in children: A meta-analysis. *Dig Dis Sci* 2002;47:2625-34.
- 1507 [189] Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute
1508 infectious diarrhea in infants and children: A systematic review of published randomized,
1509 double-blind, placebo-controlled trials. *J Pediatr Gastroenterol Nutr* 2001;33 Suppl 2:S17-25.
- 1510 [190] Van Niel CW, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute
1511 infectious diarrhea in children: A meta-analysis. *Pediatrics* 2002;109:678-84.
- 1512 [191] McFarland LV. Meta-analysis of probiotics for the prevention of traveler's diarrhea.
1513 *Travel Med Infect Dis* 2007;5:97-105.
- 1514 [192] Johnston BC, Supina AL, Ospina M, Vohra S. Probiotics for the prevention of pediatric
1515 antibiotic-associated diarrhea. *Cochrane Database Syst Rev* 2007;2:CD004827.
- 1516 [193] Johnston BC, Supina AL, Vohra S. Probiotics for pediatric antibiotic-associated diarrhea:
1517 A meta-analysis of randomized placebo-controlled trials. *CMAJ* 2006;175:377-83.
- 1518 [194] Szajewska H, Ruszczyński M, Radzikowski A. Probiotics in the prevention of antibiotic-
1519 associated diarrhea in children: A meta-analysis of randomized controlled trials. *J Pediatr*
1520 2006;149:367-72.
- 1521 [195] Cremonini F, Di Caro S, Nista EC, Bartolozzi F, Capelli G, Gasbarrini G, et al. Meta-
1522 analysis: The effect of probiotic administration on antibiotic-associated diarrhoea. *Aliment*
1523 *Pharmacol Ther* 2002;16:1461-7.
- 1524 [196] D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic
1525 associated diarrhoea: Meta-analysis. *BMJ* 2002;324:1361.
- 1526 [197] Hawrelak JA, Whitten DL, Myers SP. Is Lactobacillus rhamnosus GG effective in
1527 preventing the onset of antibiotic-associated diarrhoea: A systematic review. *Digestion*
1528 2005;72:51-6.
- 1529 [198] Szajewska H, Mrukowicz J. Meta-analysis: Non-pathogenic yeast *Saccharomyces*
1530 *boulardii* in the prevention of antibiotic-associated diarrhoea. *Aliment Pharmacol Ther*
1531 2005;22:365-72.
- 1532 [199] Bischoff SC, Escher J, Hebuterne X, Klek S, Krznaric Z, Schneider S, et al. ESPEN practical
1533 guideline: Clinical nutrition in inflammatory bowel disease. *Clin Nutr* 2020;39:632-53.
- 1534 [200] Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. Mechanisms of action of probiotics:
1535 Recent advances. *Inflamm Bowel Dis* 2009;15:300-10.

- 1536 [201] Morrow LE, Kollef MH. Probiotics in the intensive care unit: Why controversies and
1537 confusion abound. *Crit Care* 2008;12:160.
- 1538 [202] Walker WA. Mechanisms of action of probiotics. *Clin Infect Dis* 2008;46 Suppl 2:S87-
1539 91; discussion S144-51.
- 1540 [203] Roberfroid M. Prebiotics: The concept revisited. *J Nutr* 2007;137:830S-7S.
- 1541 [204] Chowdhury AH, Adiamah A, Kushairi A, Varadhan KK, Krznaric Z, Kulkarni AD, et al.
1542 Perioperative probiotics or synbiotics in adults undergoing elective abdominal surgery: A
1543 systematic review and meta-analysis of randomized controlled trials. *Ann Surg* 2019 [Epub
1544 ahead of print] doi: 10.1097/SLA.0000000000003581.
- 1545 [205] Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman
1546 HM, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: A randomised,
1547 double-blind, placebo-controlled trial. *Lancet* 2008;371:651-9.
- 1548 [206] Gou S, Yang Z, Liu T, Wu H, Wang C. Use of probiotics in the treatment of severe acute
1549 pancreatitis: A systematic review and meta-analysis of randomized controlled trials. *Crit Care*
1550 2014;18:R57.
- 1551 [207] Arvanitakis M, Ockenga J, Bezmarevic M, Gianotti L, Krznaric Z, Lobo DN, et al. ESPEN
1552 guideline on clinical nutrition in acute and chronic pancreatitis. *Clin Nutr* 2020;39:612-31.
- 1553 [208] Bischoff SC, Boirie Y, Cederholm T, Chourdakis M, Cuerda C, Delzenne NM, et al.
1554 Towards a multidisciplinary approach to understand and manage obesity and related
1555 diseases. *Clin Nutr* 2017;36:917-38.
- 1556 [209] Martin D, Roulin D, Grass F, Addor V, Ljungqvist O, Demartines N, et al. A multicentre
1557 qualitative study assessing implementation of an enhanced recovery after surgery program.
1558 *Clin Nutr* 2018;37:2172-7.
1559
1560

1561 **Legends for Figures:**

1562

1563 **Figure 1:** Prevalence of decreased eating and association with 30-day hospital mortality in
1564 preoperative, postoperative and non-surgical patients. Each dot represents 1% prevalence
1565 within the patient group. Normal eating is shown in green and is the reference category for
1566 calculation of the univariate odds ratio for death in hospital within 30 days shown as
1567 estimate with 95% confidence intervals.

1568

1569 **Figure 2:** Suggested algorithm for perioperative fluid therapy

1570

1571 **Figure 3:** Elements of Enhanced Recovery After Surgery Pathways in the pre-, intra- and post-
1572 operative periods.

1573

Journal Pre-proof

1574 **Funding:** This symposium was supported by a grant from the European Society for Clinical
1575 Nutrition and Metabolism (ESPEN).

1576

1577 **Acknowledgements:** The authors dedicate this manuscript to the memory of Mr. Ralph
1578 Stockley who sadly passed away shortly after the Symposium. Ralph was the ideal patient:
1579 stoic in adversity, yet understanding of the complexities of surgical care and always ready to
1580 provide both appreciation and constructive criticism. He will be missed greatly.

1581

1582 **Conflicts of interest:**

1583 LG, AA, RB, KD, PLG, DHJ, SK, ZK, DCM, KER, MPS, AS and RS: None to declare

1584 DNL: Unrestricted grant from B. Braun and speaker's honoraria from B. Braun, Baxter
1585 Healthcare, Fresenius Kabi and Shire for unrelated work.

1586 NEPD: Consultancy, grant and speaker's honoraria from Abbott Nutrition for unrelated work.

1587 MH: Unrestricted grants from Abbott Nutrition and Fresenius Kabi for unrelated work.

1588 OL: Consultancy fees from Nutricia, Pharmacosmos, Enhanced Medical Nutrition and Merck.

1589 Speaker's honoraria from Fresenius Kabi, Nutricia, Encare AB and B. Braun for unrelated

1590 work. He is also the Chairman of the ERAS Society and founder and shareholder of Encare

1591 AB.

1592 RJES: Grant from Novartis and speaker's honoraria from Helsinn for unrelated work.

1593 ZS: Grants from Nestle Health Science, Fresenius Kabi, Abbott Nutrition and Baxter

1594 Healthcare for unrelated work.

1595 AW: Grants from Baxter Healthcare and Danone for unrelated work. Speaker's honoraria

1596 from Baxter, B. Braun, Ethicon, Falk Foundation and Fresenius Kabi.

1597

1598

1599 **Author contributions:** All authors participated in the Symposium and were involved with the
1600 writing of the manuscript, critical revision and final approval.

1601

Table 1: Definitions of Sarcopenia (taken from the Society on Sarcopenia, Cachexia, and Wasting Disorders (SCWD) website).

Definition	Function	Muscle Mass
Sarcopenia and Frailty Research Specialist Interest Group (SIG) – cachexia-anorexia in chronic wasting disease [25]	Gait speed <0.8 m/s, OR other physical performance test	Low muscle mass (2SD)
European Working Group of Sarcopenia in Older Persons (EWGSOP) [21]	Gait speed <0.8 m/s; grip strength 40 kg males, 30 kg female	Low muscle mass (not defined)
IWGS Sarcopenia Task Force [22]	Gait speed <1.0 m/s, grip strength	Low appendicular lean mass (<7.23 kg/m ² in men, 5.67 kg/m ² in women)
Sarcopenia with limited mobility (SCWD) [10]	6-minute walk <400 m, OR gait speed <1.0 m/s	Low appendicular lean mass/height ²
Asian Working Group for Sarcopenia [23]	Gait speed <0.8 m/s; grip strength 26 kg males, 18 kg females	Low appendicular lean mass/height ²
Foundation for the National Institutes of Health [24]	Gait speed <0.8 m/s; grip strength 26 kg males, 16 kg females	Appendicular lean mass/BMI

Table 2: Pathophysiological changes of the systemic inflammatory response

Neuroendocrine changes

Fever, somnolence, fatigue and anorexia

Increased adrenal secretion of cortisol, adrenaline and glucagon

Hematopoietic changes

Anemia

Leucocytosis

Thrombocytosis

Metabolic changes

Loss of muscle and negative nitrogen balance

Increased Lipolysis

Trace metal sequestration

Diuresis

Hepatic changes

Increased blood flow

Increased acute phase protein production

Table 3: Systemic inflammation and its effects on the surgical patient

Protein catabolism after surgery leads to depletion of lean mass.

The magnitude of the post-operative systemic inflammatory response corresponds to the amount of surgical trauma.


The higher the response is associated with poorer surgical outcome.

C-reactive protein is useful in quantifying the magnitude of the post-operative systemic response.


Moderating the post-operative systemic inflammatory response (example by using a laparoscopic approach) - appears to improve surgical outcome.

Table 4: Take home messages

- History is continuity – those who don't learn from the lessons of history are condemned to repeat it.
- Preoperative muscle mass is critical to postoperative outcome.
- Sarcopenic obesity is an independent predictor of postoperative complications, especially when the host genotype is associated with weight loss and a low skeletal muscle index.
- Surgical patients who don't eat when eating is allowed and an increased length of stay when compared with those who are not allowed to eat.
- Nutritional risk score (NRS) is validated for surgical patients and should be performed at least 10 days before surgery.
- The perioperative period should be used for conditioning regimens like prehabilitation.
- High blood glucose concentrations in patients who were normoglycemic previously are associated with increased postoperative complications.
- Excess 0.9% saline is detrimental in the perioperative period and salt and water overload of >2.5 L is associated with adverse outcome.
- Enhanced Recovery After Surgery principles are appropriate for all patients, but good results are dependent on a challenging inter-disciplinary cooperation to ensure high compliance rates.
- Inflammation is a marker for surgical complications and CRP profiling is useful.
- The effects of nutrients are dissociated from nutrition and there is a role for pharmaconutrition.
- Dysbiosis contributes to inflammation – the effects of pre-, pro- and synbiotics depends on species, strains and adjuncts.
- Postoperative fatigue inhibits voluntary exercise, immobilization induces anabolic resistance, and the lower the anabolic response to feeding, the higher the muscle loss.
- Perioperative nursing in the hospital and community after discharge is a key component for good outcome.
- A strong partnership between the surgeon and patient/family/caregivers is needed to overcome complicated postoperative courses.



Journal Pre-proof



Journal Pre-proof

Preoperative**Ensure adequate hydration**

- Avoid excessive fasting
- Allow fluid intake up until 2 h before surgery
- Replace further losses in those with enterocutaneous fistulas and high output stomas

Intraoperative**Maintain fluid balance**

- Avoid excessive fluid therapy during surgery
- Use balanced fluid (e.g. Hartmann's)
- Use monitoring to guide fluid administration
- Blood transfusion as indicated for blood loss

Postoperative**Encourage early oral intake**

- Early resumption of oral intake
- Stop IV fluids once oral intake established
- Aim for a state of zero fluid balance
- If oral intake inadequate supplement with IV fluid
- If oral intake delayed, consider EN/PN